WO2005079801A1 - Pyrimidine compounds as purine receptor antagonist - Google Patents

Pyrimidine compounds as purine receptor antagonist Download PDF

Info

Publication number
WO2005079801A1
WO2005079801A1 PCT/GB2005/000498 GB2005000498W WO2005079801A1 WO 2005079801 A1 WO2005079801 A1 WO 2005079801A1 GB 2005000498 W GB2005000498 W GB 2005000498W WO 2005079801 A1 WO2005079801 A1 WO 2005079801A1
Authority
WO
WIPO (PCT)
Prior art keywords
disorder
optionally substituted
alkyl
disorders
disease
Prior art date
Application number
PCT/GB2005/000498
Other languages
French (fr)
Inventor
Roger John Gillespie
Richard Simon Todd
Gemma Caroline Stratton
Allan Michael Jordan
Original Assignee
Vernalis (R & D) Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vernalis (R & D) Ltd filed Critical Vernalis (R & D) Ltd
Priority to US10/588,757 priority Critical patent/US7875600B2/en
Priority to EP05708321A priority patent/EP1720553A1/en
Publication of WO2005079801A1 publication Critical patent/WO2005079801A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • the present invention relates to pyrimidine-4-carboxamide derivatives and their use in therapy.
  • the present invention relates to the treatment of disorders in which the reduction of purinergic neurotransmission could be beneficial.
  • the invention relates in particular to blockade of adenosine receptors and particularly adenosine A 2A receptors, and to the treatment of movement disorders such as Parkinson's disease.
  • Movement disorders constitute a serious health problem, especially amongst the elderly sector of the population. These movement disorders are often the result of brain lesions. Disorders involving the basal ganglia which result in movement disorders include Parkinson's disease, Huntington's chorea and Wilson's disease. Furthermore, dyskinesias often arise as sequelae of cerebral ischaemia and other neurological disorders.
  • Parkinson's disease There are four classic symptoms of Parkinson's disease: tremor, rigidity, akinesia and postural changes. The disease is also commonly associated with depression, dementia and overall cognitive decline. Parkinson's disease has a prevalence of 1 per 1 ,000 of the total population. The incidence increases to 1 per 100 for those aged over 60 years. Degeneration of dopaminergic neurones in the substantia nigra and the subsequent reductions in interstitial concentrations of dopamine in the striatum are critical to the development of Parkinson's disease. Some 80% of cells from the substantia nigra need to be destroyed before the clinical symptoms of Parkinson's disease are manifested.
  • L-dihydroxyphenylacetic acid L-DOPA
  • L-DOPA L-dihydroxyphenylacetic acid
  • DPA monoamine oxidase
  • dopamine receptor agonists e.g. bromocriptine and apomorphine
  • anticholinergics e.g. benztrophine, orphenadrine
  • Transmitter replacement therapy in particular does not provide consistent clinical benefit, especially after prolonged treatment when "on-off" symptoms develop, and this treatment has also been associated with involuntary movements of athetosis and chorea, nausea and vomiting. Additionally current therapies do not treat the underlying neurodegenerative disorder resulting in a continuing cognitive decline in patients.
  • Blockade of A 2 adenosine receptors has recently been implicated in the treatment of movement disorders such as Parkinson's disease (Richardson, P.J. etal., Trends Pharmacol. Sci. 1997, 18, 338-344) and in the treatment of cerebral ischaemia (Gao, Y. and Phillis, J.W., Life Sci. 1994, 55, 61-65).
  • the potential utility of adenosine A 2A receptor antagonists in the treatment of movement disorders such as Parkinson's Disease has recently been reviewed (Mally, J. and Stone, T.W., CNS Drugs, 1998, 10, 311-320).
  • Adenosine is a naturally occurring purine nucleoside which has a wide variety of well- documented regulatory functions and physiological effects.
  • the central nervous system (CNS) effects of this endogenous nucleoside have attracted particular attention in drug discovery, owing to the therapeutic potential of purinergic agents in CNS disorders (Jacobson, K.A. et al., J. Med. Chem. 1992, 35, 407-422).
  • This therapeutic potential has resulted in considerable recent research endeavour within the field of adenosine receptor agonists and antagonists (Bhagwhat, S.S.; Williams, M. Exp. Opin. Ther. Patents 1995, 5,547-558).
  • Adenosine receptors represent a subclass (P- of the group of purine nucleotide and nucleoside receptors known as purinoreceptors.
  • the main pharmacologically distinct adenosine receptor subtypes are known as A 1 ( A 2A , A 2B (of high and low affinity) and A 3 (Fredholm, B.B., etal., Pharmacol. Rev. 1994, 46, 143-156).
  • the adenosine receptors are present in the CNS (Fredholm, B.B., News Physiol. Sci., 1995, 10, 122-128).
  • P- ⁇ receptor-mediated agents The design of P- ⁇ receptor-mediated agents has been reviewed (Jacobson, K.A., Suzuki, F., Drug Dev. Res., 1997, 39, 289-300; Baraldi, P.G. etal., Curr. Med. Chem. 1995, 2, 707-722), and such compounds are claimed to be useful in the treatment of cerebral ischemia or neurodegenerative disorders, such as Parkinson's disease (Williams, M. and Burnstock, G. Purinergic Approaches Exp. Ther. (1997), 3-26. Editor: Jacobson, Kenneth A.; Jarvis, Michael F. Publisher: Wiley-Liss, New York, N.Y.)
  • xanthine derivatives such as caffeine may offer a form of treatment for attention-deficit hyperactivity disorder (ADHD).
  • ADHD attention-deficit hyperactivity disorder
  • a 2A receptor antagonist may provide an effective treatment for ADHD but without the unwanted side-effects associated with current therapy.
  • Adenosine receptors have been recognised to play an important role in regulation of sleep patterns, and indeed adenosine antagonists such as caffeine exert potent stimulant effects and can be used to prolong wakefulness (Porkka-Heiskanen, T. et al., Science, 1997, 276, 1265-1268). Recent evidence suggests that a substantial part of the actions of adenosine in regulating sleep is mediated through the adenosine A 2A receptor (Satoh, S., etal., Proc. Natl. Acad. Sci., USA, 1996). Thus, a selective A 2A receptor antagonist may be of benefit in counteracting excessive sleepiness in sleep disorders such as hypersomnia or narcolepsy.
  • a 2A receptor antagonists may offer a novel therapy for the treatment of major depression and other affective disorders in patients.
  • adenosine A 2A receptor antagonists are useful in the treatment of anxiety disorders, including panic disorder, agorophobia, obsessive compulsive disorder, social phobia, post traumatic stress disorder, generalised anxiety disorder and specific phobia.
  • adenosine A 2A receptors The pharmacology of adenosine A 2A receptors has been reviewed (Ongini, E.; Fredholm, B.B. Trends Pharmacol. Sci. 1996, 17(10), 364-372).
  • One potential underlying mechanism in the aforementioned treatment of movement disorders by the blockade of A 2 adenosine receptors is the evidence of a functional link between adenosine A 2A receptors to dopamine D 2 receptors in the CNS.
  • Some of the early studies e.g. Ferre, S. etal., Stimulation of high-affinity adenosine A 2 receptors decreases the affinity of dopamine D 2 receptors in rat striatal membranes. Proc. Natl. Acad. Sci.
  • adenosine A 2A antagonist therapy is that the underlying neurodegenerative disorder may also be treated.
  • the neuroprotective effect of adenosine A 2A antagonists has been reviewed (Ongini, E.; Adami, M.; Ferri, C; Bertorelli, R., Ann. N. Y. Acad. Sci. 1997, 825(Neuroprotective Agents), 30-48).
  • compelling recent evidence suggests that blockade of A 2A receptor function confers neuroprotection against MPTP-induced neurotoxicity in mice (Chen, J-F., J. Neurosci. 2001 , 21 , RC143).
  • a 2A receptor antagonist may offer a novel treatment for conferring neuroprotection in neurodegenerative diseases such as Parkinson's disease.
  • Xanthine derivatives have been disclosed as adenosine A 2 receptor antagonists as useful for treating various diseases caused by hyperfunctioning of adenosine A 2 receptors, such as Parkinson's disease (see, for example, EP-A-565377).
  • CSC 8-(3- chlorostyryl)caffeine
  • Theophylline (1 ,3-dimethylxanthine), a bronchodilator drug which is a mixed antagonist at adenosine A ⁇ and A 2A receptors, has been studied clinically.
  • the patients exhibited significant improvements in mean objective disability scores and 11 reported moderate or marked subjective improvement (Mally, J., Stone, T.W. J. Pharm. Pharmacol. 1994, 46, 515-517).
  • KF 17837 [(E)-8-(3,4-dimethoxystyryl)-1 ,3-dipropyl-7-methylxanthine] is a selective adenosine A 2A receptor antagonist which on oral administration significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A 2A receptor agonist, CGS 21680. KF 17837 also reduced the catalepsy induced by haloperidol and reserpine.
  • KF 17837 potentiated the anticataleptic effects of a subthreshold dose of L-DOPA plus benserazide, suggesting that KF 17837 is a centrally active adenosine A 2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A 2A receptor antagonists (Kanda, T. et al., Eur. J. Pharmacol. 1994, 256, 263-268).
  • SAR structure activity relationship
  • New non-xanthine structures sharing these pharmacological properties include SCH 58261 and its derivatives (Baraldi, P.G. etal., Pyrazolo[4,3-e]-1 ,2,4-triazolo[1 ,5- cjpyrimidine Derivatives: Potent and Selective A 2A Adenosine Antagonists. J. Med. Chem. 1996, 39, 1164-71).
  • SCH 58261 (7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-[4,3-e]- 1 ,2,4-triazolo[1 ,5-c] pyrimidine) is reported as effective in the treatment of movement disorders (Ongini, E. Drug Dev. Res. 1997, 42(2), 63-70) and has been followed up by a later series of compounds (Baraldi, P.G. etal., J. Med. Chem. 1998, 41 (12), 2126-2133).
  • WO-A-01/62233 discloses a series of cyclic heteroaromatic compounds containing at least one nitrogen atom and their use as adenosine receptor modulators.
  • FR-2201083 discloses a series of phenylpyrimidines with analgesic activity.
  • pyrimidine-4-carboxamide derivatives described herein which are structurally unrelated to known adenosine receptor antagonists, exhibit unexpected antagonist binding affinity at adenosine (P ⁇ receptors, and in particular at the adenosine A 2A receptor.
  • Such compounds may therefore be useful for the treatment of disorders in which the blocking of purine receptors, particularly adenosine receptors and more particularly adenosine A 2A receptors, is beneficial, for instance movement disorders, such as disorders of the basal ganglia which result in dyskinesias.
  • R is H or NH 2 ;
  • R 2 is optionally substituted aryl or heteroaryl attached via a carbon atom
  • R 3 is H; optionally substituted CrC 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, or C 3 -C 7 cycloalkyl, halogen; OH or OR 10 ;
  • R 4 is H, optionally substituted CrC 6 alkyl, C 3 -C 6 alkenyl, C 3 -C 6 alkynyl, C 3 -C 7 cycloalkyl, aryl or heteroaryl,
  • R 5 is H or optionally substituted CrC 6 alkyl, C 3 -C 6 alkenyl, C 3 -C 6 alkynyl, or C 3 -C 7 cycloalkyl; or R and R 5 together form a 5 or 6-membered heterocyclic ring;
  • R-io is optionally substituted C ⁇ -C 6 alkyl
  • the class of compounds (I) with which the invention is concerned are antagonists of the A 2A receptor, and in many cases are selective antagonists of the A 2A receptor over the other adenosine receptor subtypes described herein.
  • the term "carboxamide group” refers to a group of formula -CONR a Rb, wherein -NR a R b is an amino (including cyclic amino) group actually or notionally derived from ammonia or the amine HNR a R b .
  • (C a -C b )alkyr wherein a and b are integers refers to a straight or branched chain alkyl radical having from a to b carbon atoms.
  • a is 1 and b is 6, for example, the term includes methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec- butyl, t-butyl, n-pentyl and n-hexyl.
  • (C a -C b )alkenyl wherein a and b are integers refers to a straight or branched chain alkenyl moiety having from a to b carbon atoms having at least one double bond of either E or Z stereochemistry where applicable.
  • the term includes, for example, vinyl, allyl, 1- and 2-butenyl and 2-methyl-2-propenyl.
  • cycloalkyl refers to a saturated carbocyclic radical having from 3-8 carbon atoms and includes, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.
  • cycloalkenyl refers to a carbocyclic radical having from 3-8 carbon atoms containing at least one double bond, and includes, for example, cyclopentenyl, cyclohexenyl, cycloheptenyl and cyclooctenyl.
  • aryl refers to a mono-, bi- or tri-cyclic carbocyclic aromatic radical and includes mono or bicyclic aromatic rings fused to a cycloalkyl ring.
  • Illustrative of such radicals are phenyl, biphenyl and napthyl.
  • Carbocyclic refers to a cyclic radical whose ring atoms are all carbon, and includes monocyclic aryl, cycloalkyl, and cycloalkenyl radicals.
  • heteroaryl refers to a mono-, bi- or tri-cyclic aromatic radical containing one or more heteroatoms selected from S, N and O, and includes mono or bicyclic of the foregoing type fused to a cycloalkyl ring.
  • Illustrative of such radicals are thienyl, benzthienyl, furyl, benzfuryl, pyrrolyl, imidazolyl, benzimidazolyl, thiazolyl, benzthiazolyl, isothiazolyl, benzisothiazolyl, pyrazolyl, oxazolyl, benzoxazolyl, isoxazolyl, benzisoxazolyl, isothiazolyl, triazolyl, benztriazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, indolyl and indazolyl.
  • heterocyclyl or “heterocyclic” includes “heteroaryl” as defined above, and in particular refers to a mono-, bi- or tri-cyclic non-aromatic radical containing one or more heteroatoms selected from S, N and O, and to groups consisting of a monocyclic non-aromatic radical containing one or more such heteroatoms which is covalently linked to another such radical or to a monocyclic carbocyclic radical.
  • radicals are pyrrolyl, furanyl, thienyl, piperidinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, pyrazolyl, pyridinyl, pyrrolidinyl, pyrimidinyl, morpholinyl, piperazinyl, indolyl, morpholinyl, benzfuranyl, pyranyl, isoxazolyl, benzimidazolyl, methylenedioxyphenyl, ethylenedioxyphenyl, maleimido and succinimido groups.
  • substituted as applied to any moiety herein means substituted with at least one substituent, for example selected from (C CeJalkyl, (CrC 6 )alkoxy, hydroxy, hydroxy(CrC 6 )alkyl, mercapto, mercapto(CrC 6 )alkyl, (CrC 6 )alkylthio, halo (including fluoro and chloro), trifluoromethyl, trifluoromethoxy, nitro, nitrile (-CN), oxo, phenyl, monocyclic heterocyclic having 5- or 6 ring members, -COOH, -COOR A , -COR A , -S0 2 R A , -CONH 2 , -S0 2 NH 2 , -CONHR A , -S0 2 NHR A , -CONR A R B , -S0 2 NR A R B ,
  • an “optional substituent” may be one of the foregoing substituent groups. Where the optional substituent is phenyl, monocyclic heterocyclic having 5- or 6 ring members, then it too may be substituted by any of the foregoing except phenyl and monocyclic heterocyclic having 5- or 6 ring members.
  • salt includes base addition, acid addition and quaternary salts.
  • Compounds of the invention which are acidic can form salts, including pharmaceutically or veterinarily acceptable salts, with bases such as alkali metal hydroxides, e.g. sodium and potassium hydroxides; alkaline earth metal hydroxides e.g. calcium, barium and magnesium hydroxides; with organic bases e.g. N-ethyl piperidine, dibenzylamine and the like.
  • bases such as alkali metal hydroxides, e.g. sodium and potassium hydroxides; alkaline earth metal hydroxides e.g. calcium, barium and magnesium hydroxides; with organic bases e.g. N-ethyl piperidine, dibenzylamine and the like.
  • Those compounds (I) which are basic can form salts, including pharmaceutically or veterinarily acceptable salts with inorganic acids, e.g.
  • hydrohalic acids such as hydrochloric or hydrobromic acids, sulphuric acid, nitric acid or phosphoric acid and the like
  • organic acids e.g. with acetic, tartaric, succinic, fumaric, maleic, malic, salicylic, citric, methanesulphonic and p-toluene sulphonic acids and the like.
  • 'solvate' is used herein to describe a molecular complex comprising the compound of the invention and a stoichiometric amount of one or more pharmaceutically acceptable solvent molecules, for example, ethanol.
  • solvent molecules for example, ethanol.
  • 'hydrate' is employed when said solvent is water.
  • So-called 'pro-drugs' of the compounds of formula (I) are also within the scope of the invention.
  • certain derivatives of compounds of formula (I) which may have little or no pharmacological activity themselves can, when administered into or onto the body, be converted into compounds of formula (I) having the desired activity, for example, by hydrolytic cleavage.
  • Such derivatives are referred to as 'prodrugs'.
  • Further information on the use of prodrugs may be found in Pro-drugs as Novel Delivery Systems. Vol. 14, ACS Symposium Series (T. Higuchi and W. Stella) and Bioreversible Carriers in Drug Design. Pergamon Press, 1987 (ed. E. B. Roche, American Pharmaceutical Association).
  • Prodrugs in accordance with the invention can, for example, be produced by replacing appropriate functionalities present in the compounds of formula (I) with certain moieties known to those skilled in the art as 'pro-moieties' as described, for example, in Design of Prodrugs by H. Bundgaard (Elsevier, 1985).
  • metabolites of compounds of formula (I), that is, compounds formed in vivo upon administration of the drug are also included within the scope of the invention.
  • Some examples of metabolites include
  • R ⁇ is hydrogen or NH 2 .
  • NH 2 is marginally preferred over hydrogen.
  • R 2 is selected from aryl and heteroaryl attached via a carbon atom, including substituted aryl and heteroaryl.
  • R 2 may be optionally substituted phenyl or an optionally substituted monocyclic or bicyclic heteroaryl group such as optionally substituted furyl, thienyl, thiazolyl, oxazolyl, imidazolyl, pyridyl, indolyl or benzofuranyl.
  • furyl preferably 2-furyl
  • thiazolyl preferably 2-thiazolyl
  • Optional substituents which may be present in R 2 include CrC 3 alkyl such as methyl and ethyl, CrC 3 alkoxy such as methoxy and ethoxy, cyano (-CN), chloro, bromo, fluoro, trifluoromethyl, and carboxamide groups such as -CONR A R B where R A and R B are independently hydrogen or C C 3 alkyl.
  • R A and R B are independently hydrogen or C C 3 alkyl.
  • R 2 groups are 2-furyl, 5-methyl-2 furyl, 2- thiazolyl, 4-methyl-2-thiazolyl, phenyl, 3-cyano-phenyl and o-methyl-phenyl.
  • R 3 is H; optionally substituted C C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, or C 3 -C 7 cycloalkyl, halogen; OH or OR ⁇ 0 wherein R 10 is optionally substituted C C 6 alkyl such as ethyl, methyl, or n-or iso-propyl.
  • R 3 is H, CrC 6 alkyI, halo substituted CrC 6 alkyl, C 3 -C 6 cycloalkyl, or halogen.
  • R 3 groups include H, methyl, ethyl, n- and isopropyl, cyclopropyl, n-sec and tert- butyl, trifloromethyl, chloro, bromo and fluoro, and of the foregoing, hydrogen, methyl, chloro and bromo are presently preferred.
  • R is H, optionally substituted Ci- Cealkyl, C 3 -C 6 alkenyl, C 3 -C 6 alkynyl, C 3 -C 7 cycloalkyl, aryl or heteroaryl, or together with R 5 forms a 5 or 6-membered heterocyclic ring.
  • R 4 is heteroaryl or includes a heteroaryl ring (for example where R 4 is heteroaryl(CrC 6 alkyl)-), such rings include optionally substituted pyridyl, furanyl, thienyl, isoxazolyl, thiazolyl, pyrrolyl, imidazolyl, pyrazolyl, pyrazinyl, pyrimidinyl, benzimidazolyl, indolyl, benzthiazolyl, benzthiadiazolyl, quinolyl, and isoquinolyl.
  • optionally substituted pyridyl especially 2-pyridyl
  • imidazolyl, pyrazolyl, and isoxazolyl are most preferred at present.
  • R 4 be C ⁇ -C 6 alkyl, substituted by aryl or heteroaryl, with the aryl or heteroaryl ring itself being optionally substituted.
  • R groups are included arylmethyl and heteroarylmethyl, again with optional substitution in the aryl and heteroaryl rings.
  • Phenyl is a preferred aryl ring, and heteroaryl rings in this category of R groups include those listed in the preceding paragraph.
  • an aryl or heteroaryl group constituting or present in R 4 may be optionally substituted. Typically, only one substituent group is present.
  • Optional substituents in this context include any of those referred to herein including C C 3 alkyl such as methyl and ethyl, C-
  • R 5 is H or optionally substituted Ci- Cealkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, or C 3 -C 7 cycloalkyl, or together with R 4 forms a 5 or 6- membered heterocyclic ring.
  • R 5 is hydrogen.
  • R and R 5 may be linked to form a 5 or 6-membered heterocyclic ring, said heterocyclic ring may be saturated, partially unsaturated or aromatic, and is preferably saturated.
  • Said heterocyclic ring may contain one or more additional heteroatom(s) preferably selected from N, O and S.
  • the heterocyclic ring contains no further heteroatoms, and in another the ring contains further heteroatoms as, for example, in morpholino, thiomorpholino, piperazino and piperazinyl substituted with, for example, C
  • the heterocyclic ring is unsubstituted.
  • the 5 or 6-membered heterocyclic ring may be fused to an aromatic ring system, particularly a monocyclic ring system (preferably containing 6 ring atoms, such as phenyl) to form a multicyclic moiety, such as dihydroindolyl, dihydroisoindolyl, tetrahydroquinolinyl or tetrahydroisoquinolinyl.
  • aromatic ring system particularly a monocyclic ring system (preferably containing 6 ring atoms, such as phenyl) to form a multicyclic moiety, such as dihydroindolyl, dihydroisoindolyl, tetrahydroquinolinyl or tetrahydroisoquinolinyl.
  • the compounds of formula (I) may be in the form of a racemic mixture of pairs of enantiomers or in enantiomerically pure form.
  • a method of treating or preventing a disorder in which the blocking of purine receptors, particularly adenosine receptors and more particularly adenosine A 2A receptors, is beneficial comprising administration to a subject in need of such treatment an effective dose of a compound of formula (I) as defined above, or a pharmaceutically acceptable salt or prodrug thereof.
  • the disorder with which the use or method of the invention is concerned may be caused by the hyperfunctioning of the purine receptors.
  • the use or method of the invention may be employed in respect of a human or animal subject, more preferably a mammal, more preferably a human subject.
  • the disorders of particular interest in connection with the use or method of the invention is concerned are those in which the blocking of purine receptors, particularly adenosine receptors and more particularly adenosine A 2A receptors, may be beneficial. These may include movement disorders such as Parkinson's disease, drug-induced Parkinsonism, post-encephalitic Parkinsonism, Parkinsonism induced by poisoning (for example MPTP, manganese, carbon monoxide) and post-traumatic Parkinson's disease (punch-drunk syndrome).
  • Other movement disorders in which the blocking of purine receptors, may be of benefit include progressive supernuclear palsy, Huntingtons disease, multiple system atrophy, corticobasal degeneration, Wilsons disease, Hallerrorden-Spatz disease, progressive pallidal atrophy, Dopa-responsive dystonia-Parkinsonism, spasticity or other disorders of the basal ganglia which result in abnormal movement or posture.
  • the present invention may also be effective in treating Parkinson's with on-off phenomena; Parkinson's with freezing (end of dose deterioration); and Parkinson's with prominent dyskinesias.
  • a method of treating or preventing movement disorders comprising administration to a subject in need of such treatment an effective dose of a compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof.
  • the compounds of formula (I) may be used or administered in combination with one or more additional drugs useful in the treatment of movement disorders, such as L-DOPA or a dopamine agonist, the components being in the same formulation or in separate formulations for administration simultaneously or sequentially.
  • additional drugs useful in the treatment of movement disorders such as L-DOPA or a dopamine agonist
  • disorders in which the blocking of purine receptors, particularly adenosine receptors and more particularly adenosine A 2A receptors may be beneficial include anxiety disorders, including panic disorder, agorophobia, obsessive compulsive disorder, social phobia, post traumatic stress disorder, generalised anxiety disorder and specific phobia.
  • anxiety disorders including panic disorder, agorophobia, obsessive compulsive disorder, social phobia, post traumatic stress disorder, generalised anxiety disorder and specific phobia.
  • the use and method of treatment of the invention is also applicable in the case of noninflammatory pain, particulary neuropathic pain, including trigeminal neuralgia, phantom limb pain, spinal cord injury pain, post-herpetic pain and HIV pain.
  • affective disorders including mood disorders such as bipolar disorder, seasonal affective disorder, depression, manic depression, atypical depression and monodepressive disease; central and peripheral nervous system degenerative disorders including corticobasal degeneration, demyelinating disease (multiple sclerosis, disseminated sclerosis),
  • a method of neuroprotection comprising administration to a subject in need of such treatment an effective dose of a compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof.
  • the medicament for or method of neuroprotection may be of use in the treatment of subjects who are suffering from or at risk from a neurodegenerative disorder, such as a movement disorder.
  • the present invention also includes novel compounds forming a subset of the compounds of formula (I) as defined above. Accordingly, the invention also provides compounds of formula (I) PROVIDED THAT: (a) R 2 is not an optionally substituted pyrazolopyridine ring system; (b) when F ⁇ and R 3 are hydrogen and R 2 is unsubstituted phenyl then -NR 4 R 5 is not -NH 2 , NHCH 3 or -N(CH 3 ) 2 ; and (c) when Ri is -NH 2 and R 3 is hydrogen, then R 2 is not phenyl or phenyl substituted by one or more substituents selected from hologen, hydroxy, C C 6 alkyl, C C 6 alkoxy, nitro, -NH 2 , or -NHCOCH 3 .
  • R 2 - R 5 in the novel compounds of the invention are as discussed above, including the preferred and specific classes and examples of those substituents.
  • the substituent(s) in the phenyl ring may be selected from, for example, methylenedioxy, CrC 6 alkylthio, trifluromethyl, trifluoromethoxy, nitrile (-CN), oxo, COR A , -CONHR A , -CONR A R B , -NHR A , NR A R B , - NHCOR 0 , -NHCOOR A , -NR B COOR A wherein R A and R B are independently a C r C 6 alkyl group such as methyl, ethyl, n- or iso-propyl, and wherein R c is
  • Compounds of formula (1) may be prepared from compounds of formula (5) by standard methods used for coupling carboxylic acids and amines. Such coupling reactions would include reaction of a carboxylic acid derivative such as an imidazolide prepared with N,N'- carbonyldiimidazole or a mixed anhydride prepared with an alkyl chloroformate and a trialkylamine base or an acyl chloride prepared from a chlorinating source such as oxalyl chloride with an appropriate amine, or by direct coupling of an appropriate amine in the presence of a standard coupling reagent such as dicyclohexylcarbodiimide and a nucleophilic catalyst such as 4-dimethylaminopyridine.
  • a carboxylic acid derivative such as an imidazolide prepared with N,N'- carbonyldiimidazole or a mixed anhydride prepared with an alkyl chloroformate and a trialkylamine base or an acyl chloride prepared from a chlorinating
  • Compounds of formula (5) may be prepared from compounds of formula (4) by standard methods such as hydrolysis with a mineral acid such as sulfuric or hydrochloric acid.
  • Compounds of formula (4) may be prepared from compounds of formula (3) by standard methods such as cyanation with an alkali metal cyanide such as sodium cyanide or an organic source of cyanide such as tetraethylammonium cyanide in the presence of a tertiary amine base such as 1 ,4-diazabicyclo[2.2.2]octane or triethylamine.
  • aryl or heteroaryl coupling reactions would include reaction with an appropriate aryl or heteroarylboronic acid derivative, an aryl or heteroaryltrialkylstannane derivative or an aryl or heteroarylzinc halide derivative in the presence of a suitable catalyst such as a palladium complex.
  • compounds of formula (1), where R 3 is halogen may be prepared from compounds of formula (1 ), where R 3 is H, by standard methods such as halogenation with N-bromo- or N-chlorosuccinnimide.
  • Compounds of formula (3), where R 3 is H or alkyl may be prepared from compounds of formula (10), where R 3 is H or alkyl, by standard methods such as chlorination with POCI 3 .
  • Compounds of formula (10), where R 3 is H or alkyl may be prepared from compounds of formula (9), where R 3 is H or alkyl, by standard methods such as condensation with guanidine or formamidine
  • Compounds of formula (5), where R 3 is H or alkyl may be synthesised from compounds of formula (7) as described above.
  • Compounds of formula (7), where R 3 is H or alkyl may be prepared from compounds of formula (12), where R 3 is H or alkyl, by standard methods such as condensation with guanidine or formamidine.
  • Compounds of formula (12), where R 3 is H or alkyl may be prepared from compounds of formula (8), where R 3 is H or alkyl, by standard methods such as deprotonation with a base such as NaH followed by treatment with a reagent such as diethyl oxalate.
  • Any suitable route of administration may be employed for providing the patient with an effective dosage of a compound of formula (I) .
  • oral, rectal, parenteral (intravenous, intramuscular), transdermal, subcutaneous, and the like may be employed.
  • Dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules, patches, and the like.
  • the most suitable route in any given case will depend on the severity of the condition being treated.
  • the most preferred route of administration of the present invention is the oral route.
  • the compositions may be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy.
  • the compounds of formula (I) can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques.
  • the carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g. oral or parenteral (e.g. intravenous).
  • any of the usual pharmaceutical media may be employed as carriers, such as, for example, water, glycols, oils, alcohols, flavouring agents, preservatives, colouring agents, and the like in the case of oral liquid preparations (such as suspensions, solutions and elixirs) or aerosols; or carriers such as starches, sugars, micro-crystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like may be used in the case of oral solid preparations such as, for example, powders, capsules, and tablets, with the solid oral preparations being preferred over the liquid preparations.
  • the most preferred solid oral preparation is tablets. Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage unit form in which case solid pharmaceutical carriers are employed. If desired, tablets may be coated by standard aqueous or non-aqueous techniques.
  • the compounds of formula (I) may also be administered by controlled release means and/or delivery devices such as those described in United States Patent Nos.: 3,845,770; 3,916,899; 3,536,809; 3,598,123; 3,630,200; 4,008,719; 4,687,660; and 4,769,027, the disclosures of which are hereby incorporated by reference.
  • compositions employed in the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets, or tablets, or aerosol sprays each containing a predetermined amount of the active ingredient as a powder or granules, a solution or a suspension in an aqueous liquid, an oil-in-water emulsion, or a water-in-oil liquid emulsion.
  • Such compositions may be prepared by any of the methods of pharmacy, but all methods include the step of bringing the active ingredient into association with the carrier which constitutes one or more necessary ingredients.
  • the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired presentation.
  • a tablet may be prepared by compression or moulding, optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, a lubricant, an inert diluent, and/or a surface active or dispersing agent.
  • Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
  • Guanidine carbonate (3.48 g, 19.32 mmol) was suspended in EtOH (100 mL) and toluene (20 mL) and 50 mL of the solvent was distilled off using a Dean & Stark apparatus.
  • the suspension was cooled to 40 °C, treated with a solution of ethyl ⁇ -oxo-2- thiazolepropionate (7.7 g, 38.65 mmol) in EtOH (20 mL), refluxed for 40 h, cooled, treated with water (50 mL) and refluxed for 30 min.
  • the suspension was cooled to 0 °C, treated with a solution of cone.
  • 2-Dimethylamino-6(5-methylfuran-2-yl)pyrimidine-4-carboxylic acid lithium salt A mixture of 2-dimethylamino-6-(5-methylfuran-2-yl)pyrimidine-4-carbonitrile (0.68 g, 2.98 mmol) in 6-M HCI (40 mL) and THF (10 mL) was refluxed for 6 h, cooled, concentrated in vacuo and the residue subjected to ion-exchange column chromatography (Isolute® Flash SCX-2; DCM;MeOH then 1-M NH 3 :MeOH).
  • Preparative LC-MS was performed at ambient temperature on a Waters FractionLynx MS autopurification system using a Luna 5 ⁇ m, C18(2), 100 mm x 21.2 mm i.d. column from Phenomenex.
  • Solvent A water + 0.08% v/v formic acid
  • solvent B 95% methanol-water + 0.08% v/v formic acid
  • flow rate 20 ml min -1 .
  • the instrument incorporated a photo diode array detector (210-400 nm) and a MicroMass ZQ mass spectrometer.
  • the ionisation method was positive ion electrospray and the molecular weight scan range was 150- 1000. Collection was triggered by detection of the selected mass ion.
  • Solvents A - Water + 10mmol NH 4 OAc + 0.08% (v/v) formic acid B - 95% Acetonitrile / 5% Solvent A + 0.08% (v/v) formic acid
  • Binding Affinities at hA 2A Receptors The compounds were examined in an assay measuring in vitro binding to human adenosine A 2A receptors by determining the displacement of the adenosine A 2A receptor selective radioligand [ 3 H]-CGS 21680 using standard techniques.
  • the compounds of the above examples have a Kj of ⁇ 5 ⁇ M in this assay, demonstrating binding affinity for the human adenosine A 2A receptor.
  • the compound of Example 1 has a K of ⁇ 50 nM in this assay, demonstrating potent binding affinity for the human adenosine A 2A receptor.
  • adenosine antagonists such as theophylline
  • dopamine antagonists such as haloperidol
  • rodents rodents
  • mice Female TO mice (25-30g) obtained from Harlan, UK, are used for all experiments. Animals are housed in groups of 8 [cage size - 40 (width) x 40 (length) x 20 ( height)cm] under 12 h light/dark cycle (lights on 08:00hr), in a temperature (20 ⁇ 2°C) and humidity (55 ⁇ 15%) controlled environment. Animals have free access to food and water, and are allowed at least 3 days to acclimatize after delivery before experimental use.
  • Drugs Liquid injectable haloperidol (1 ml Serenance ampoules from Baker Norton, Harlow, Essex, each containing haloperidol BP 5 mg) are diluted to a final concentration of 0.02 mg/ml using saline.
  • Test compounds are typically prepared as aqueous suspensions in 1 % methyl cellulose. All compounds are administered orally in a volume of 10 ml/kg.
  • mice are administered 0.2 mg/kg haloperidol, a dose that reduces baseline locomotor activity by at least 50 %.
  • Test substances are typically administered 5 - 60 min. prior to testing.
  • the animals are then placed individually into clean, clear polycarbonate cages [20 (width) x 40 (length) x 20 (height) cm, with a flat perforated, Perspex lid].
  • Horizontal locomotor activity is determined by placing the cages within a frame containing a 4 x 7 array of photocells linked to a computer, which tabulates beam breaks. Mice are left undisturbed to explore for up to 1 h, and the number of beams breaks made during this period serves as a record of locomotor activity which is compared with data for control animals for statistically significant differences.
  • the compound of example 1 above is orally active in this model at a dose of 30 mg/kg:-
  • An alternative model of Parkinson's Disease for assessment of the compounds of the invention is as follows.
  • Parkinson's disease is a progressive neurodegenerative disorder characterised by symptoms of muscle rigidity, tremor, paucity of movement (hypokinesia), and postural instability. It has been established for some time that the primary deficit in PD is a loss of dopaminergic neurones in the substantia nigra which project to the striatum, and indeed a substantial proportion of striatal dopamine is lost (ca 80-85%) before symptoms are observed. The loss of striatal dopamine results in abnormal activity of the basal ganglia, a series of nuclei which regulate smooth and well co-ordinated movement (Blandini F. etal., Glutamate and Parkinson's Disease. Mol. Neurobiol. 1996, 12, 73 - 94). The neurochemical deficits seen in Parkinson's disease can be reproduced by local injection of the dopaminergic neurotoxin 6-hydroxydopamine into brain regions containing either the cell bodies or axonal fibres of the nigrostriatal neurones.
  • mice Male Sprague-Dawley rats, obtained from Charles River, are used for all experiments. Animals are housed in groups of 5 under 12hr light/dark cycle (lights on 08:00hr), in a temperature (20 ⁇ 2°C) and humidity (55 ⁇ 15%) controlled environment. Animals have free access to food and water, and are allowed at least 7 days to acclimatize after delivery before experimental use.
  • 6- OHDA Ascorbic acid, desipramine, 6-OHDA and apomorphine (Sigma-Aldrich, Poole, UK).
  • 6- OHDA is freshly prepared as a solution in 0.2% ascorbate at a concentration of 4 mg/mL prior to surgery.
  • Desipramine is dissolved in warm saline, and administered in a volume of 1 ml/kg.
  • Apomorphine is dissolved in 0.02% ascorbate and administered in a volume of 2 ml_/kg.
  • Test compounds are suspended in 1 % methyl cellulose and injected in a volume of 2 mL kg.
  • mice 15 minutes prior to surgery, animals are given an intraperitoneal injection of the noradrenergic uptake inhibitor desipramine (25 mg/kg) to prevent damage to non- dopamine neurones.
  • Animals are then placed in an anaesthetic chamber and anaesthetised using a mixture of oxygen and isoflurane. Once unconscious, the animals are transferred to a stereotaxic frame, where anaesthesia is maintained through a mask. The top of the animal's head is shaved and sterilised using an iodine solution. Once dry, a 2 cm long incision is made along the midline of the scalp and the skin retracted and clipped back to expose the skull. A small hole is then drilled through the skill above the injection site.
  • desipramine 25 mg/kg
  • the injection cannula is slowly lowered to position above the right medial forebrain bundle at -3.2 mm anterior posterior, -1.5 mm medial lateral from bregma, and to a depth of 7.2 mm below the duramater. 2 minutes after lowing the cannula, 2 ⁇ L of 6-OHDA solution is infused at a rate of 0.5 ⁇ L/min over 4 minutes, yielding a final dose of 8 ⁇ g. The cannula is then left in place for a further 5 minutes to facilitate diffusion before being slowly withdrawn. The skin is then sutured shut using Ethicon W501 Mersilk, and the animal removed from the strereotaxic frame and returned to its homecage. The rats are allowed 2 weeks to recover from surgery before behavioural testing.
  • Rotational behaviour is measured using an eight station rotameter system provided by Med Associates, San Diego, USA. Each station is comprised of a stainless steel bowl (45 cm diameter x 15 cm high) enclosed in a transparent Plexiglas cover running around the edge of the bowl, and extending to a height of 29 cm. To assess rotation, rats are placed in cloth jacket attached to a spring tether connected to optical rotameter positioned above the bowl, which assesses movement to the left or right either as partial (45 s ) or full (360 Q ) rotations. All eight stations are interfaced to a computer that tabulated data.
  • rats are initially habituated to the apparatus for 15 minutes on four consecutive days. On the test day, rats are given an intraperitoneal injection of test compound 30 minutes prior to testing. Immediately prior to testing, animals are given a subcutaneous injection of a subthreshold dose of apomorphine, then placed in the harness and the number of rotations recorded for one hour. The total number of full contralateral rotations during the hour test period serves as an index of antiparkinsonian drug efficacy.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Compounds of formula (I); wherein R1 is H or NHZ; R2 is optionally substituted aryl or heteroaryl attached via a carbon atom; R3 is H; optionally substituted C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, or C3­ C7 cycloalkyl, halogen; OH or OR,or R4 is H, optionally substituted C1-C6alkyl, C3­ C6alkenyl, C3-C6alkynyl, C3-C7 cycloalkyl, aryl or heteroaryl, R5 is H or optionally substituted C1-C6alkyl, C3-C6alkenyl, C3-C6alkynyl, or C3-C7 cycloalkyl; or R4 and R5 together form a 5 or 6-membered heterocyclic ring; and R10 is optionally substituted C1-C6alkyl; are purine receptor, particularly adenosine receptor antagonists, useful for treatment of, inter alia, movement disorders such as Parkinsons disease.

Description

Pyrimidine Compounds as Purine Receptor Antagonists
The present invention relates to pyrimidine-4-carboxamide derivatives and their use in therapy. In particular, the present invention relates to the treatment of disorders in which the reduction of purinergic neurotransmission could be beneficial. The invention relates in particular to blockade of adenosine receptors and particularly adenosine A2A receptors, and to the treatment of movement disorders such as Parkinson's disease.
Movement disorders constitute a serious health problem, especially amongst the elderly sector of the population. These movement disorders are often the result of brain lesions. Disorders involving the basal ganglia which result in movement disorders include Parkinson's disease, Huntington's chorea and Wilson's disease. Furthermore, dyskinesias often arise as sequelae of cerebral ischaemia and other neurological disorders.
There are four classic symptoms of Parkinson's disease: tremor, rigidity, akinesia and postural changes. The disease is also commonly associated with depression, dementia and overall cognitive decline. Parkinson's disease has a prevalence of 1 per 1 ,000 of the total population. The incidence increases to 1 per 100 for those aged over 60 years. Degeneration of dopaminergic neurones in the substantia nigra and the subsequent reductions in interstitial concentrations of dopamine in the striatum are critical to the development of Parkinson's disease. Some 80% of cells from the substantia nigra need to be destroyed before the clinical symptoms of Parkinson's disease are manifested.
Current strategies for the treatment of Parkinson's disease are based on transmitter replacement therapy (L-dihydroxyphenylacetic acid (L-DOPA)), inhibition of monoamine oxidase (e.g. Deprenyl®), dopamine receptor agonists (e.g. bromocriptine and apomorphine) and anticholinergics (e.g. benztrophine, orphenadrine). Transmitter replacement therapy in particular does not provide consistent clinical benefit, especially after prolonged treatment when "on-off" symptoms develop, and this treatment has also been associated with involuntary movements of athetosis and chorea, nausea and vomiting. Additionally current therapies do not treat the underlying neurodegenerative disorder resulting in a continuing cognitive decline in patients. Despite new drug approvals, there is still a medical need in terms of improved therapies for movement disorders, especially Parkinson's disease. In particular, effective treatments requiring less frequent dosing, effective treatments which are associated with less severe side-effects, and effective treatments which control or reverse the underlying neurodegenerative disorder, are required.
Blockade of A2 adenosine receptors has recently been implicated in the treatment of movement disorders such as Parkinson's disease (Richardson, P.J. etal., Trends Pharmacol. Sci. 1997, 18, 338-344) and in the treatment of cerebral ischaemia (Gao, Y. and Phillis, J.W., Life Sci. 1994, 55, 61-65). The potential utility of adenosine A2A receptor antagonists in the treatment of movement disorders such as Parkinson's Disease has recently been reviewed (Mally, J. and Stone, T.W., CNS Drugs, 1998, 10, 311-320).
Adenosine is a naturally occurring purine nucleoside which has a wide variety of well- documented regulatory functions and physiological effects. The central nervous system (CNS) effects of this endogenous nucleoside have attracted particular attention in drug discovery, owing to the therapeutic potential of purinergic agents in CNS disorders (Jacobson, K.A. et al., J. Med. Chem. 1992, 35, 407-422). This therapeutic potential has resulted in considerable recent research endeavour within the field of adenosine receptor agonists and antagonists (Bhagwhat, S.S.; Williams, M. Exp. Opin. Ther. Patents 1995, 5,547-558).
Adenosine receptors represent a subclass (P- of the group of purine nucleotide and nucleoside receptors known as purinoreceptors. The main pharmacologically distinct adenosine receptor subtypes are known as A1 ( A2A, A2B (of high and low affinity) and A3 (Fredholm, B.B., etal., Pharmacol. Rev. 1994, 46, 143-156). The adenosine receptors are present in the CNS (Fredholm, B.B., News Physiol. Sci., 1995, 10, 122-128).
The design of P-\ receptor-mediated agents has been reviewed (Jacobson, K.A., Suzuki, F., Drug Dev. Res., 1997, 39, 289-300; Baraldi, P.G. etal., Curr. Med. Chem. 1995, 2, 707-722), and such compounds are claimed to be useful in the treatment of cerebral ischemia or neurodegenerative disorders, such as Parkinson's disease (Williams, M. and Burnstock, G. Purinergic Approaches Exp. Ther. (1997), 3-26. Editor: Jacobson, Kenneth A.; Jarvis, Michael F. Publisher: Wiley-Liss, New York, N.Y.)
It has been speculated that xanthine derivatives such as caffeine may offer a form of treatment for attention-deficit hyperactivity disorder (ADHD). A number of studies have demonstrated a beneficial effect of caffeine on controlling the symptoms of ADHD
(Garfinkel, B.D. etal., Psychiatry, 1981 , 26, 395-401). Antagonism of adenosine receptors is thought to account for the majority of the behavioural effects of caffeine in humans and thus blockade of adenosine A2A receptors may account for the observed effects of caffeine in ADHD patients. Therefore a selective A2A receptor antagonist may provide an effective treatment for ADHD but without the unwanted side-effects associated with current therapy.
Adenosine receptors have been recognised to play an important role in regulation of sleep patterns, and indeed adenosine antagonists such as caffeine exert potent stimulant effects and can be used to prolong wakefulness (Porkka-Heiskanen, T. et al., Science, 1997, 276, 1265-1268). Recent evidence suggests that a substantial part of the actions of adenosine in regulating sleep is mediated through the adenosine A2A receptor (Satoh, S., etal., Proc. Natl. Acad. Sci., USA, 1996). Thus, a selective A2A receptor antagonist may be of benefit in counteracting excessive sleepiness in sleep disorders such as hypersomnia or narcolepsy.
It has recently been observed that patients with major depression demonstrate a blunted response to adenosine agonist-induced stimulation in platelets, suggesting that a dysregulation of A2A receptor function may occur during depression (Berk, M. et al, 2001 , Eur. Neuropsychopharmacol. 11 , 183-186). Experimental evidence in animal models has shown that blockade of A2A receptor function confers antidepressant activity (El Yacoubi, M et al. Br. J. Pharmacol. 2001 , 134, 68-77). Thus, A2A receptor antagonists may offer a novel therapy for the treatment of major depression and other affective disorders in patients.
Also recently, from patent publication WO 2004/108137 (Kyowa Hakko Kogyo), it is now considered that adenosine A2A receptor antagonists are useful in the treatment of anxiety disorders, including panic disorder, agorophobia, obsessive compulsive disorder, social phobia, post traumatic stress disorder, generalised anxiety disorder and specific phobia.
The pharmacology of adenosine A2A receptors has been reviewed (Ongini, E.; Fredholm, B.B. Trends Pharmacol. Sci. 1996, 17(10), 364-372). One potential underlying mechanism in the aforementioned treatment of movement disorders by the blockade of A2 adenosine receptors is the evidence of a functional link between adenosine A2A receptors to dopamine D2 receptors in the CNS. Some of the early studies (e.g. Ferre, S. etal., Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes. Proc. Natl. Acad. Sci. U.S.A. 1991 , 88, 7238-41) have been summarised in two more recent articles (Fuxe, K. et al., Adenosine Adenine Nucleotides Mol. Biol. Integr. Physiol., [Proc. Int. Symp.], 5th (1995), 499-507. Editors: Belardinelli, Luiz; Pelleg, Amir. Publisher: Kluwer, Boston, Mass.; Ferre, S. et al., Trends Neurosci. 1997, 20, 482-487).
As a result of these investigations into the functional role of adenosine A2A receptors in the CNS, especially in vivo studies linking A2 receptors with catalepsy (Ferre etal., Neurosci. Lett. 1991, 130, 162-4; Mandhane, S.N. etal., Eur. J. Pharmacol. 1997, 328, 135-141) investigations have been made into agents which selectively bind to adenosine A2A receptors as potentially effective treatments for Parkinson's disease.
While many of the potential drugs for treatment of Parkinson's disease have shown benefit in the treatment of movement disorders, an advantage of adenosine A2A antagonist therapy is that the underlying neurodegenerative disorder may also be treated. The neuroprotective effect of adenosine A2A antagonists has been reviewed (Ongini, E.; Adami, M.; Ferri, C; Bertorelli, R., Ann. N. Y. Acad. Sci. 1997, 825(Neuroprotective Agents), 30-48). In particular, compelling recent evidence suggests that blockade of A2A receptor function confers neuroprotection against MPTP-induced neurotoxicity in mice (Chen, J-F., J. Neurosci. 2001 , 21 , RC143). In addition, several recent studies have shown that consumption of dietary caffeine, a known adenosine A2A receptor antagonist, is associated with a reduced risk of Parkinson's disease in man (Ascherio, A. et al, Ann Neurol., 2001 , 50, 56-63; Ross G W, et al., JAMA, 2000, 283, 2674-9). Thus, A2A receptor antagonists may offer a novel treatment for conferring neuroprotection in neurodegenerative diseases such as Parkinson's disease.
Xanthine derivatives have been disclosed as adenosine A2 receptor antagonists as useful for treating various diseases caused by hyperfunctioning of adenosine A2 receptors, such as Parkinson's disease (see, for example, EP-A-565377).
One prominent xanthine-derived adenosine A2A selective antagonist is CSC [8-(3- chlorostyryl)caffeine] (Jacobson et al., FEBS Lett, 1993, 323, 141 -144).
Theophylline (1 ,3-dimethylxanthine), a bronchodilator drug which is a mixed antagonist at adenosine A^ and A2A receptors, has been studied clinically. To determine whether a formulation of this adenosine receptor antagonist would be of value in Parkinson's disease an open trial was conducted on 15 Parkinsonian patients, treated for up to 12 weeks with a slow release oral theophylline preparation (150 mg/day), yielding serum theophylline levels of 4.44 mg/L after one week. The patients exhibited significant improvements in mean objective disability scores and 11 reported moderate or marked subjective improvement (Mally, J., Stone, T.W. J. Pharm. Pharmacol. 1994, 46, 515-517).
KF 17837 [(E)-8-(3,4-dimethoxystyryl)-1 ,3-dipropyl-7-methylxanthine] is a selective adenosine A2A receptor antagonist which on oral administration significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680. KF 17837 also reduced the catalepsy induced by haloperidol and reserpine. Moreover, KF 17837 potentiated the anticataleptic effects of a subthreshold dose of L-DOPA plus benserazide, suggesting that KF 17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists (Kanda, T. et al., Eur. J. Pharmacol. 1994, 256, 263-268). The structure activity relationship (SAR) of KF 17837 has been published (Shimada, J. etal., Bioorg. Med. Chem. Lett. 1997, 7, 2349-2352). Recent data has also been provided on the A2A receptor antagonist KW- 6002 (Kuwana, Y et al., Soc. Neurosci. Abstr. 1997, 23, 119.14; and Kanda, T. et al., Ann. Neurol. 1998, 43(4), 507-513).
New non-xanthine structures sharing these pharmacological properties include SCH 58261 and its derivatives (Baraldi, P.G. etal., Pyrazolo[4,3-e]-1 ,2,4-triazolo[1 ,5- cjpyrimidine Derivatives: Potent and Selective A2A Adenosine Antagonists. J. Med. Chem. 1996, 39, 1164-71). SCH 58261 (7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-[4,3-e]- 1 ,2,4-triazolo[1 ,5-c] pyrimidine) is reported as effective in the treatment of movement disorders (Ongini, E. Drug Dev. Res. 1997, 42(2), 63-70) and has been followed up by a later series of compounds (Baraldi, P.G. etal., J. Med. Chem. 1998, 41 (12), 2126-2133). WO-A-01/62233 discloses a series of cyclic heteroaromatic compounds containing at least one nitrogen atom and their use as adenosine receptor modulators. FR-2201083 discloses a series of phenylpyrimidines with analgesic activity.
The foregoing discussion indicates that a potentially effective treatment for movement disorders in humans would comprise agents which act as antagonists at adenosine A2A receptors.
It has now been found that the pyrimidine-4-carboxamide derivatives described herein, which are structurally unrelated to known adenosine receptor antagonists, exhibit unexpected antagonist binding affinity at adenosine (P^ receptors, and in particular at the adenosine A2A receptor. Such compounds may therefore be useful for the treatment of disorders in which the blocking of purine receptors, particularly adenosine receptors and more particularly adenosine A2A receptors, is beneficial, for instance movement disorders, such as disorders of the basal ganglia which result in dyskinesias.
According to the present invention there is provided the use of a compound of formula (1):
Figure imgf000008_0001
wherein
R is H or NH2;
R2 is optionally substituted aryl or heteroaryl attached via a carbon atom;
R3 is H; optionally substituted CrC6alkyl, C2-C6alkenyl, C2-C6alkynyl, or C3-C7 cycloalkyl, halogen; OH or OR10; R4 is H, optionally substituted CrC6alkyl, C3-C6alkenyl, C3-C6alkynyl, C3-C7 cycloalkyl, aryl or heteroaryl,
R5 is H or optionally substituted CrC6alkyl, C3-C6alkenyl, C3-C6alkynyl, or C3-C7 cycloalkyl; or R and R5 together form a 5 or 6-membered heterocyclic ring;
R-io is optionally substituted Cι-C6alkyl;
and pharmaceutically acceptable salts and prodrugs thereof, in the manufacture of a medicament for the treatment or prevention of a disorder in which the blocking of purine receptors is beneficial, PROVIDED THAT when R2 is optionally substituted aryl the said use is not the manufacture of a medicament for the treatment or prevention of inflammatory pain.
The class of compounds (I) with which the invention is concerned are antagonists of the A2A receptor, and in many cases are selective antagonists of the A2A receptor over the other adenosine receptor subtypes described herein. As used herein the term "carboxamide group" refers to a group of formula -CONRaRb, wherein -NRaRb is an amino (including cyclic amino) group actually or notionally derived from ammonia or the amine HNRaRb.
As used herein, the term "(Ca-Cb)alkyr wherein a and b are integers refers to a straight or branched chain alkyl radical having from a to b carbon atoms. Thus when a is 1 and b is 6, for example, the term includes methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec- butyl, t-butyl, n-pentyl and n-hexyl.
As used herein the term "(Ca-Cb)alkenyl" wherein a and b are integers refers to a straight or branched chain alkenyl moiety having from a to b carbon atoms having at least one double bond of either E or Z stereochemistry where applicable. The term includes, for example, vinyl, allyl, 1- and 2-butenyl and 2-methyl-2-propenyl.
As used herein the term "cycloalkyl" refers to a saturated carbocyclic radical having from 3-8 carbon atoms and includes, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.
As used herein the term "cycloalkenyl" refers to a carbocyclic radical having from 3-8 carbon atoms containing at least one double bond, and includes, for example, cyclopentenyl, cyclohexenyl, cycloheptenyl and cyclooctenyl.
As used herein the term "aryl" refers to a mono-, bi- or tri-cyclic carbocyclic aromatic radical and includes mono or bicyclic aromatic rings fused to a cycloalkyl ring. Illustrative of such radicals are phenyl, biphenyl and napthyl.
As used herein the term "carbocyclic" refers to a cyclic radical whose ring atoms are all carbon, and includes monocyclic aryl, cycloalkyl, and cycloalkenyl radicals.
As used herein the term "heteroaryl" refers to a mono-, bi- or tri-cyclic aromatic radical containing one or more heteroatoms selected from S, N and O, and includes mono or bicyclic of the foregoing type fused to a cycloalkyl ring. Illustrative of such radicals are thienyl, benzthienyl, furyl, benzfuryl, pyrrolyl, imidazolyl, benzimidazolyl, thiazolyl, benzthiazolyl, isothiazolyl, benzisothiazolyl, pyrazolyl, oxazolyl, benzoxazolyl, isoxazolyl, benzisoxazolyl, isothiazolyl, triazolyl, benztriazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, indolyl and indazolyl. As used herein the unqualified term "heterocyclyl" or "heterocyclic" includes "heteroaryl" as defined above, and in particular refers to a mono-, bi- or tri-cyclic non-aromatic radical containing one or more heteroatoms selected from S, N and O, and to groups consisting of a monocyclic non-aromatic radical containing one or more such heteroatoms which is covalently linked to another such radical or to a monocyclic carbocyclic radical. Illustrative of such radicals are pyrrolyl, furanyl, thienyl, piperidinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, pyrazolyl, pyridinyl, pyrrolidinyl, pyrimidinyl, morpholinyl, piperazinyl, indolyl, morpholinyl, benzfuranyl, pyranyl, isoxazolyl, benzimidazolyl, methylenedioxyphenyl, ethylenedioxyphenyl, maleimido and succinimido groups.
Unless otherwise specified in the context in which it occurs, the term "substituted" as applied to any moiety herein means substituted with at least one substituent, for example selected from (C CeJalkyl, (CrC6)alkoxy, hydroxy, hydroxy(CrC6)alkyl, mercapto, mercapto(CrC6)alkyl, (CrC6)alkylthio, halo (including fluoro and chloro), trifluoromethyl, trifluoromethoxy, nitro, nitrile (-CN), oxo, phenyl, monocyclic heterocyclic having 5- or 6 ring members, -COOH, -COORA, -CORA, -S02RA, -CONH2, -S02NH2, -CONHRA, -S02NHRA, -CONRARB, -S02NRARB, -NH2, -NHRA, -NRARB, -OCONH2, -OCONHRA , -OCONRARB, -NHCORA, -NRBCORA, -NHCOORA, -NRBCOORA, -NHS02RA, -NRBS02RA, -NHCONH2, -NRACONH2, -NHCONHR6 -NRACONHRB, -NHCONRARB or -NRACONRARB wherein RA and RB are independently a (d-C6)alkyl group. An "optional substituent" may be one of the foregoing substituent groups. Where the optional substituent is phenyl, monocyclic heterocyclic having 5- or 6 ring members, then it too may be substituted by any of the foregoing except phenyl and monocyclic heterocyclic having 5- or 6 ring members.
As used herein the term "salt" includes base addition, acid addition and quaternary salts. Compounds of the invention which are acidic can form salts, including pharmaceutically or veterinarily acceptable salts, with bases such as alkali metal hydroxides, e.g. sodium and potassium hydroxides; alkaline earth metal hydroxides e.g. calcium, barium and magnesium hydroxides; with organic bases e.g. N-ethyl piperidine, dibenzylamine and the like. Those compounds (I) which are basic can form salts, including pharmaceutically or veterinarily acceptable salts with inorganic acids, e.g. with hydrohalic acids such as hydrochloric or hydrobromic acids, sulphuric acid, nitric acid or phosphoric acid and the like, and with organic acids e.g. with acetic, tartaric, succinic, fumaric, maleic, malic, salicylic, citric, methanesulphonic and p-toluene sulphonic acids and the like. For a review on suitable salts, see Handbook of Pharmaceutical Salts: Properties. Selection, and Use by Stahl and Wermuth (Wiley-VCH, Weinheim, Germany, 2002).
The term 'solvate' is used herein to describe a molecular complex comprising the compound of the invention and a stoichiometric amount of one or more pharmaceutically acceptable solvent molecules, for example, ethanol. The term 'hydrate' is employed when said solvent is water.
Compounds with which the invention is concerned which may exist in one or more stereoisomeric form, because of the presence of asymmetric atoms or rotational restrictions, can exist as a number of stereoisomers with R or S stereochemistry at each chiral centre or as atropisomeres with R or S stereochemistry at each chiral axis. The invention includes all such enantiomers and diastereoisomers and mixtures thereof
So-called 'pro-drugs' of the compounds of formula (I) are also within the scope of the invention. Thus certain derivatives of compounds of formula (I) which may have little or no pharmacological activity themselves can, when administered into or onto the body, be converted into compounds of formula (I) having the desired activity, for example, by hydrolytic cleavage. Such derivatives are referred to as 'prodrugs'. Further information on the use of prodrugs may be found in Pro-drugs as Novel Delivery Systems. Vol. 14, ACS Symposium Series (T. Higuchi and W. Stella) and Bioreversible Carriers in Drug Design. Pergamon Press, 1987 (ed. E. B. Roche, American Pharmaceutical Association).
Prodrugs in accordance with the invention can, for example, be produced by replacing appropriate functionalities present in the compounds of formula (I) with certain moieties known to those skilled in the art as 'pro-moieties' as described, for example, in Design of Prodrugs by H. Bundgaard (Elsevier, 1985).
Also included within the scope of the invention are metabolites of compounds of formula (I), that is, compounds formed in vivo upon administration of the drug. Some examples of metabolites include
(i) where the compound of formula (I) contains a methyl group, an hydroxymethyl derivative thereof (-CH3 -> -CH2OH): (ii) where the compound of formula (I) contains an alkoxy group, an hydroxy derivative thereof (-OR -> -OH);
(iii) where the compound of formula (I) contains a tertiary amino group, a secondary amino derivative thereof (-NR1R2 -> -NHR1 or -NHR2);
(iv) where the compound of formula (I) contains a secondary amino group, a primary derivative thereof (-NHR1 -> -NH2);
(v) where the compound of formula (I) contains a phenyl moiety, a phenol derivative thereof (-Ph -> -PhOH); and
(vi) where the compound of formula (I) contains an amide group, a carboxylic acid derivative thereof (-CONH2 -> COOH).
The group f?j
In the compounds in accordance with the invention, R^ is hydrogen or NH2. At present, NH2 is marginally preferred over hydrogen.
TAie group R2
In the compounds in accordance with the invention, R2 is selected from aryl and heteroaryl attached via a carbon atom, including substituted aryl and heteroaryl. For example, R2 may be optionally substituted phenyl or an optionally substituted monocyclic or bicyclic heteroaryl group such as optionally substituted furyl, thienyl, thiazolyl, oxazolyl, imidazolyl, pyridyl, indolyl or benzofuranyl. At present optionally substituted phenyl, furyl (preferably 2-furyl) and thiazolyl (preferably 2-thiazolyl) are preferred. Optional substituents which may be present in R2 include CrC3 alkyl such as methyl and ethyl, CrC3 alkoxy such as methoxy and ethoxy, cyano (-CN), chloro, bromo, fluoro, trifluoromethyl, and carboxamide groups such as -CONRARB where RA and RB are independently hydrogen or C C3 alkyl. Where optional substituents are present in monocyclic R2, mono or disubstitution are presently preferred, although of the disubstitution options ortho-ortho disubstitution is less preferred at present. Examples of particular R2 groups are 2-furyl, 5-methyl-2 furyl, 2- thiazolyl, 4-methyl-2-thiazolyl, phenyl, 3-cyano-phenyl and o-methyl-phenyl.
The group R3
In the compounds in accordance with the invention, R3 is H; optionally substituted C C6alkyl, C2-C6alkenyl, C2-C6alkynyl, or C3-C7 cycloalkyl, halogen; OH or ORι0 wherein R10 is optionally substituted C C6alkyl such as ethyl, methyl, or n-or iso-propyl. Presently it is preferred that R3 is H, CrC6alkyI, halo substituted CrC6alkyl, C3-C6 cycloalkyl, or halogen. Specific R3 groups include H, methyl, ethyl, n- and isopropyl, cyclopropyl, n-sec and tert- butyl, trifloromethyl, chloro, bromo and fluoro, and of the foregoing, hydrogen, methyl, chloro and bromo are presently preferred.
The group R4
In the compounds in accordance with the invention, R is H, optionally substituted Ci- Cealkyl, C3-C6alkenyl, C3-C6alkynyl, C3-C7 cycloalkyl, aryl or heteroaryl, or together with R5 forms a 5 or 6-membered heterocyclic ring.
Where R4 is heteroaryl or includes a heteroaryl ring (for example where R4 is heteroaryl(CrC6alkyl)-), such rings include optionally substituted pyridyl, furanyl, thienyl, isoxazolyl, thiazolyl, pyrrolyl, imidazolyl, pyrazolyl, pyrazinyl, pyrimidinyl, benzimidazolyl, indolyl, benzthiazolyl, benzthiadiazolyl, quinolyl, and isoquinolyl. Of the foregoing, optionally substituted pyridyl (especially 2-pyridyl), imidazolyl, pyrazolyl, and isoxazolyl are most preferred at present.
Presently it is preferred that R4 be Cι-C6alkyl, substituted by aryl or heteroaryl, with the aryl or heteroaryl ring itself being optionally substituted. Within this category of R groups are included arylmethyl and heteroarylmethyl, again with optional substitution in the aryl and heteroaryl rings. Phenyl is a preferred aryl ring, and heteroaryl rings in this category of R groups include those listed in the preceding paragraph.
As indicated above, an aryl or heteroaryl group constituting or present in R4 may be optionally substituted. Typically, only one substituent group is present. Optional substituents in this context include any of those referred to herein including C C3 alkyl such as methyl and ethyl, C-|-C3 alkoxy such as methoxy and ethoxy, C C3 alkoxy(CrC3 alkyl)- such as C C3 alkoxymethyl including methoxymethyl, ethoxymethyl, n- and iso- propoxy methyl, and methoxy-(CrC3 alkyl)- such as methoxyethyl, a chloro, bromo, fluoro, trifluoromethyl, amino groups such as -NRARB, carboxamide groups such as -CONRARB and reverse carboxamide groups such as -NRACORB where RA and RB are independently hydrogen or C|-C3 alkyl or together form a 5 or 6-membered heterocyclic ring wherein said heterocyclic ring may be saturated, partially unsaturated or aromatic, and is preferably saturated, and wherein said heterocyclic ring may contain one or more additional heteroatom(s) preferably selected from N, O and S, and in one embodiment contains no further heteroatoms, and in one embodiment is unsubstituted.
The group R5 In the compounds in accordance with the invention, R5 is H or optionally substituted Ci- Cealkyl, C2-C6alkenyl, C2-C6alkynyl, or C3-C7 cycloalkyl, or together with R4 forms a 5 or 6- membered heterocyclic ring. Presently it is preferred that R5 is hydrogen.
The groups R4 and Rs together In the compounds in accordance with the invention, R and R5 may be linked to form a 5 or 6-membered heterocyclic ring, said heterocyclic ring may be saturated, partially unsaturated or aromatic, and is preferably saturated. Said heterocyclic ring may contain one or more additional heteroatom(s) preferably selected from N, O and S. In one embodiment, the heterocyclic ring contains no further heteroatoms, and in another the ring contains further heteroatoms as, for example, in morpholino, thiomorpholino, piperazino and piperazinyl substituted with, for example, C|-C3 alkyl on the second ring nitrogen. In one embodiment, the heterocyclic ring is unsubstituted. In one embodiment, the 5 or 6-membered heterocyclic ring may be fused to an aromatic ring system, particularly a monocyclic ring system (preferably containing 6 ring atoms, such as phenyl) to form a multicyclic moiety, such as dihydroindolyl, dihydroisoindolyl, tetrahydroquinolinyl or tetrahydroisoquinolinyl.
Where chiral the compounds of formula (I) may be in the form of a racemic mixture of pairs of enantiomers or in enantiomerically pure form.
According to a further aspect of the present invention there is provided a method of treating or preventing a disorder in which the blocking of purine receptors, particularly adenosine receptors and more particularly adenosine A2A receptors, is beneficial, the method comprising administration to a subject in need of such treatment an effective dose of a compound of formula (I) as defined above, or a pharmaceutically acceptable salt or prodrug thereof.
The disorder with which the use or method of the invention is concerned may be caused by the hyperfunctioning of the purine receptors.
The use or method of the invention may be employed in respect of a human or animal subject, more preferably a mammal, more preferably a human subject. The disorders of particular interest in connection with the use or method of the invention is concerned are those in which the blocking of purine receptors, particularly adenosine receptors and more particularly adenosine A2A receptors, may be beneficial. These may include movement disorders such as Parkinson's disease, drug-induced Parkinsonism, post-encephalitic Parkinsonism, Parkinsonism induced by poisoning (for example MPTP, manganese, carbon monoxide) and post-traumatic Parkinson's disease (punch-drunk syndrome).
Other movement disorders in which the blocking of purine receptors, may be of benefit include progressive supernuclear palsy, Huntingtons disease, multiple system atrophy, corticobasal degeneration, Wilsons disease, Hallerrorden-Spatz disease, progressive pallidal atrophy, Dopa-responsive dystonia-Parkinsonism, spasticity or other disorders of the basal ganglia which result in abnormal movement or posture. The present invention may also be effective in treating Parkinson's with on-off phenomena; Parkinson's with freezing (end of dose deterioration); and Parkinson's with prominent dyskinesias.
Thus, according to a further aspect of the present invention, there is provided use of a compound of formula (I) as defined above, or a pharmaceutically acceptable salt or prodrug thereof in the manufacture of a medicament for the treatment or prevention of movement disorders in a subject.
According to a further aspect of the invention there is provided a method of treating or preventing movement disorders comprising administration to a subject in need of such treatment an effective dose of a compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof.
The compounds of formula (I) may be used or administered in combination with one or more additional drugs useful in the treatment of movement disorders, such as L-DOPA or a dopamine agonist, the components being in the same formulation or in separate formulations for administration simultaneously or sequentially.
Other disorders in which the blocking of purine receptors, particularly adenosine receptors and more particularly adenosine A2A receptors may be beneficial include anxiety disorders, including panic disorder, agorophobia, obsessive compulsive disorder, social phobia, post traumatic stress disorder, generalised anxiety disorder and specific phobia. The use and method of treatment of the invention is also applicable in the case of noninflammatory pain, particulary neuropathic pain, including trigeminal neuralgia, phantom limb pain, spinal cord injury pain, post-herpetic pain and HIV pain.
The use and method of the invention may also be useful in the case of affective disorders including mood disorders such as bipolar disorder, seasonal affective disorder, depression, manic depression, atypical depression and monodepressive disease; central and peripheral nervous system degenerative disorders including corticobasal degeneration, demyelinating disease (multiple sclerosis, disseminated sclerosis),
Freidrich's ataxia, motoneurone disease (amyotrophic lateral sclerosis, progressive bulbar atrophy), multiple system atrophy, myelopathy, radiculopathy, peripheral neuropathy (diabetic neuropathy, tabes dorsalis, drug-induced neuropathy, vitamin deficiency), systemic lupus erythamatosis, granulomatous disease, olivo-ponto-cerebellar atrophy, progressive pallidal atrophy, progressive supranuclear palsy, spasticity; schizophrenia and related psychoses; cognitive and/or memory impairment disorders including dementia, Alzheimers Disease, Frontotemporal dementia, multi-infarct dementia, AIDS dementia, dementia associated with Huntingtons Disease, Lewy body dementia, senile dementia, age-related memory impairment, cognitive impairment associated with dementia, Korsakoff syndrome, dementia pugilans; attention disorders such as attention-deficit hyperactivity disorder (ADHD), attention deficit disorder, minimal brain dysfunction, brain- injured child syndrome, hyperkinetic reaction childhood, and hyperactive child syndrome; central nervous system injury including traumatic brain injury, neurosurgery (surgical trauma), neuroprotection for head injury, raised intracranial pressure, cerebral oedema, hydrocephalus, spinal cord injury; cerebral ischaemia including transient ischaemic attack, stroke (thrombotic stroke, ischaemic stroke, embolic stroke, haemorrhagic stroke, lacunar stroke) subarachnoid haemorrhage, cerebral vasospasm, neuroprotection for stroke, perinatal asphyxia, drowning, cardiac arrest, subdural haematoma; myocardial ischaemia; muscle ischaemia; sleep disorders such as hypersomnia, narcolepsy and restless legs syndrome; eye disorders such as retinal ischaemia-reperfusion injury and diabetic neuropathy; cardiovascular disorders such as claudication and hypotension; and diabetes and its complications. According to a further aspect of the invention there is provided use of a compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof in the manufacture of a medicament for neuroprotection in a subject.
According to a further aspect of the invention there is provided a method of neuroprotection comprising administration to a subject in need of such treatment an effective dose of a compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof.
The medicament for or method of neuroprotection may be of use in the treatment of subjects who are suffering from or at risk from a neurodegenerative disorder, such as a movement disorder.
The present invention also includes novel compounds forming a subset of the compounds of formula (I) as defined above. Accordingly, the invention also provides compounds of formula (I) PROVIDED THAT: (a) R2 is not an optionally substituted pyrazolopyridine ring system; (b) when F^ and R3 are hydrogen and R2 is unsubstituted phenyl then -NR4R5 is not -NH2, NHCH3 or -N(CH3)2; and (c) when Ri is -NH2 and R3 is hydrogen, then R2 is not phenyl or phenyl substituted by one or more substituents selected from hologen, hydroxy, C C6 alkyl, C C6 alkoxy, nitro, -NH2, or -NHCOCH3.
Subject to the exclusions imposed by provisos (a) - (c), preferred substituent groups R2 - R5 in the novel compounds of the invention are as discussed above, including the preferred and specific classes and examples of those substituents. In the case where Ri is -NH2 and R3 is hydrogen, and R2 is substituted phenyl, the substituent(s) in the phenyl ring may be selected from, for example, methylenedioxy, CrC6 alkylthio, trifluromethyl, trifluoromethoxy, nitrile (-CN), oxo, CORA, -CONHRA, -CONRARB, -NHRA, NRARB, - NHCOR0, -NHCOORA, -NRBCOORA wherein RA and RB are independently a CrC6 alkyl group such as methyl, ethyl, n- or iso-propyl, and wherein Rc is a C2-C6 alkyl group such as ethyl, or n- or iso-propyl.
There are multiple synthetic strategies for the synthesis of the compounds (I) with which the present invention is concerned, but all rely on known chemistry, known to the synthetic organic chemist. Thus, compounds according to formula (I) can be synthesised according to procedures described in the standard literature and are well-known to the one skilled in the art. Typical literature sources are "Advanced organic chemistry", 4th Edition (Wiley), J March, "Comprehensive Organic Transformation, 2nd Edition (Wiley), R.C. Larock , "Handbook of Heterocyclic Chemistry", 2nd Edition (Pergamon), A.R. Katritzky), review articles such as found in "Synthesis", "Ace. Chem. Res." , "Chem. Rev", or primary literature sources identified by standard literature searches online or from secondary sources such as "Chemical Abstracts" or "Beilsteirf'. Suitable reaction schemes are as follows
Reaction Scheme 1
Figure imgf000018_0001
Compounds of formula (1) may be prepared from compounds of formula (5) by standard methods used for coupling carboxylic acids and amines. Such coupling reactions would include reaction of a carboxylic acid derivative such as an imidazolide prepared with N,N'- carbonyldiimidazole or a mixed anhydride prepared with an alkyl chloroformate and a trialkylamine base or an acyl chloride prepared from a chlorinating source such as oxalyl chloride with an appropriate amine, or by direct coupling of an appropriate amine in the presence of a standard coupling reagent such as dicyclohexylcarbodiimide and a nucleophilic catalyst such as 4-dimethylaminopyridine.
Compounds of formula (5) may be prepared from compounds of formula (4) by standard methods such as hydrolysis with a mineral acid such as sulfuric or hydrochloric acid. Compounds of formula (4) may be prepared from compounds of formula (3) by standard methods such as cyanation with an alkali metal cyanide such as sodium cyanide or an organic source of cyanide such as tetraethylammonium cyanide in the presence of a tertiary amine base such as 1 ,4-diazabicyclo[2.2.2]octane or triethylamine.
Compounds of formula (3) are either known in the literature or may be prepared from the known compound of formula (2) by standard methods such as aryl or heteroaryl coupling reactions. Such aryl or heteroaryl coupling reactions would include reaction with an appropriate aryl or heteroarylboronic acid derivative, an aryl or heteroaryltrialkylstannane derivative or an aryl or heteroarylzinc halide derivative in the presence of a suitable catalyst such as a palladium complex.
In Reaction Scheme (1) compounds of formula (1), where R3 is halogen, may be prepared from compounds of formula (1 ), where R3 is H, by standard methods such as halogenation with N-bromo- or N-chlorosuccinnimide.
Compounds of formula (5), where R3 is H, may alternatively be synthesised by standard methods such as those illustrated in Reaction Scheme 2.
Reaction Scheme 2
Figure imgf000019_0001
(6) (7) (5)
In Reaction Scheme (2) compounds of formula (5), where R3 is H, may be prepared from compounds of formula (7), where R3 is H, by standard methods such as hydrolysis with aqueous alkali such as lithium, sodium or potassium hydroxide.
Compounds of formula (7), where R3 is H, may be prepared from compounds of formula
(6), where R3 is H, by standard methods such as aryl or heteroaryl coupling reactions as described above. Compounds of formula (6), where R3 is H, are known in the literature. Compounds of formula (3), where R3 is H or alkyl, may alternatively be synthesised by standard methods such as those illustrated in Reaction Scheme 3.
Reaction Scheme 3
Figure imgf000020_0001
(8) (9) (10) (3)
Compounds of formula (3), where R3 is H or alkyl, may be prepared from compounds of formula (10), where R3 is H or alkyl, by standard methods such as chlorination with POCI3. Compounds of formula (10), where R3 is H or alkyl, may be prepared from compounds of formula (9), where R3 is H or alkyl, by standard methods such as condensation with guanidine or formamidine
Compounds of formula (9), where R3 is H or alkyl, are known in the literature or may be prepared from compounds of formula (8), where R3 is H or alkyl, by standard methods such as deprotonation with a base such as NaH followed by treatment with a carboxylating reagent such as diethyl carbonate.
Compounds of formula (8), where R3 is H or alkyl, are either known in the literature or may be prepared by standard methods
Compounds of formula (5), where R3 is H or alkyl, may alternatively be synthesised by standard methods such as those illustrated in Reaction Scheme 4.
Reaction Scheme 4
R2 R2 R R2
Figure imgf000020_0002
(8) (12) (7) (5)
Compounds of formula (5), where R3 is H or alkyl, may be synthesised from compounds of formula (7) as described above. Compounds of formula (7), where R3 is H or alkyl, may be prepared from compounds of formula (12), where R3 is H or alkyl, by standard methods such as condensation with guanidine or formamidine.
Compounds of formula (12), where R3 is H or alkyl, may be prepared from compounds of formula (8), where R3 is H or alkyl, by standard methods such as deprotonation with a base such as NaH followed by treatment with a reagent such as diethyl oxalate.
Compounds with which the invention is concerned may be presented in a pharmaceutical composition comprising a compound of formula (l)as defined and discussed above in combination with a pharmaceutically acceptable carrier or excipient.
Any suitable route of administration may be employed for providing the patient with an effective dosage of a compound of formula (I) . For example, oral, rectal, parenteral (intravenous, intramuscular), transdermal, subcutaneous, and the like may be employed. Dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules, patches, and the like. The most suitable route in any given case will depend on the severity of the condition being treated. The most preferred route of administration of the present invention is the oral route. The compositions may be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy.
In practical use, the compounds of formula (I) can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g. oral or parenteral (e.g. intravenous). In preparing the compositions for oral dosage form, any of the usual pharmaceutical media may be employed as carriers, such as, for example, water, glycols, oils, alcohols, flavouring agents, preservatives, colouring agents, and the like in the case of oral liquid preparations (such as suspensions, solutions and elixirs) or aerosols; or carriers such as starches, sugars, micro-crystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like may be used in the case of oral solid preparations such as, for example, powders, capsules, and tablets, with the solid oral preparations being preferred over the liquid preparations. The most preferred solid oral preparation is tablets. Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage unit form in which case solid pharmaceutical carriers are employed. If desired, tablets may be coated by standard aqueous or non-aqueous techniques.
In addition to the common dosage forms set out above, the compounds of formula (I) may also be administered by controlled release means and/or delivery devices such as those described in United States Patent Nos.: 3,845,770; 3,916,899; 3,536,809; 3,598,123; 3,630,200; 4,008,719; 4,687,660; and 4,769,027, the disclosures of which are hereby incorporated by reference.
Pharmaceutical compositions employed in the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets, or tablets, or aerosol sprays each containing a predetermined amount of the active ingredient as a powder or granules, a solution or a suspension in an aqueous liquid, an oil-in-water emulsion, or a water-in-oil liquid emulsion. Such compositions may be prepared by any of the methods of pharmacy, but all methods include the step of bringing the active ingredient into association with the carrier which constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired presentation.
For example, a tablet may be prepared by compression or moulding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, a lubricant, an inert diluent, and/or a surface active or dispersing agent. Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
The invention is further defined by reference to the following examples. It will be apparent to those skilled in the art that many modifications, both to materials and methods, may be practised without departing from the purpose and interest of this invention.
EXAMPLES
Synthetic Examples The invention is illustrated with reference to the following Examples, as set out in Table 1.
Table 1
Example Structure Compound Name
2-Amino-N-(2-fluorobenzyl)-6-(2- furyl)pyrimidine-4-carboxamide
2-Amino-N-(3,4-difluorophenyl)-6-(2- furyl)pyrimidine-4-carboxamide
2-Amino-6-(2-furyl)-N-(3- methoxybenzyl)pyrimidine-4-carboxamide
Figure imgf000023_0001
2-Amino-6-(2-furyl)-N,N-dimethylpyrimidine- Ν ΝH, 4-carboxamide l-(2-Amino-6-(2-furyl)pyrimidin-4- ylcarbonyl)piperidine
2-Amino-6-(2-furyl)-N-(2- methoxybenzyl)pyrimidine-4-carboxamide
2-Amino-6-(2-furyl)-N-(2- furylmethyl)pyrimidine-4-carboxamide
2-Amino-6-(2-furyl)pyrirnidme-4- carboxamide
Figure imgf000023_0002
Figure imgf000024_0001
Figure imgf000025_0001
-
Figure imgf000026_0001
Figure imgf000027_0001
Figure imgf000028_0001
6-(2-Amino-6-(2-furyl)pyrimidine-4- carboxamidomethyl)pyridin-2-ylmethyl dimethylcarbamate
2-Amino-6-(2-furyl)-N-(isoqumolm-3- ylmethyl)pyrimidine-4-carboxamide
l-(2-Amino-6-(2-furyl)pyrimidin-4- ylcarbonyl)-4-(2-pyridyl)piperazine
2-Amino-6-(2-furyl)-N-(quinolin-2- ylmethyl)pyrimidine-4-carboxamide
2-Amino-N-(benzothiazol-2-ylmethyl)-6-(2- furyl)pyrimidine-4-carboxamide
2-Amino-N-(6-cyclopropylmethoxymethyl-3- methylpyridin-2-ylmethyl)-6-(2- furyl)pyrimidine-4-carboxamide
(S)-2-Amino-6-(2-furyl)-N-(l- phenylethyl)pyrimidine-4-carboxamide
2-Amino-N-(4-chlorobenzyl)-6-(2- furyl)pyrimidine-4-carboxamide
2-Ammo-N-(4-fluorobenzyl)-6-(2- furyl)pyrimidine-4-carboxamide
Figure imgf000029_0001
Figure imgf000030_0001
Figure imgf000031_0001
Figure imgf000032_0001
Figure imgf000033_0001
Figure imgf000034_0001
Figure imgf000035_0001
Figure imgf000036_0001
Figure imgf000037_0001
Figure imgf000038_0001
Figure imgf000039_0001
Figure imgf000040_0001
Figure imgf000041_0001
Figure imgf000042_0001
Figure imgf000043_0001
Figure imgf000044_0001
The general synthetic methods used for the preparation of these Examples are set out below as Methods A to AK. Table 2 sets out the Method used and yield obtained for each Example, together with the analytical data.
Method A 2-Amino-4-chloro-6-(2-furyl)pyrimidine
A solution of 2-(tributylstannyl)furan (35.7 g, 100 mmol) in DMF (100 mL) was treated with 2-amino-4,6-dichloropyrimidine (16.4 g, 100 mmol) and dichlorobis(triphenylphosphine)palladium (II) (3.51 g, 5.0 mmol). The suspension was stirred at 80 SC for 18 h, allowed to cool to room temperature and poured onto ice (400 g). The solid precipitate was filtered off, washed with water, dried in air, and the filtrate was extracted with EtOAc (300 mL), washed with water (100 mL), mixed with the solid precipitate and concentrated. The crude product was purified by chromatography [Si02; EtOAc:toluene (0:1 - 1 :9 - 2:3)] and the material with Rf 0.23 (isopropyl ether) was triturated with isohexane to give the title compound (11.1 g, 57 %) as a yellow solid; mp. 133 - 140 SC; NMR δH (400 MHz, DMSO) 6.70 (1 H, q, J2.0 Hz), 6.95 (1 H, s), 7.16 (2H, br s), 7.27 (1H, d, 3.6 Hz) and 7.92 (1 H, t, J 1.0 Hz).
Method B
2-Amino-6-(2-furyl)pyrϊmidine-4-carbonitrile
A solution of 2-amino-4-chloro-6-(2-furyl)pyrimidine (9.78 g, 50.0 mmol) in DMSO (200 mL) was treated with sodium cyanide (14.7 g, 300 mmol) and 1 ,4- diazabicyclo[2.2.2]octane (DABCO) (0.56 g, 5.0 mmol). The suspension was stirred for 4 days, and more DABCO (5.04 g, 45 mmol) and DMSO (100 mL) were added. The suspension was stirred for a further 2 days, poured onto a mixture of ice (750 g) and water (750 mL), the crude product was filtered off, washed with water and MeCN, and dried in air to give the title compound (7.1 g, 77 %) as a brown solid; m.p. 193 - 194 2C; NMR δH (400 MHz, DMSO) 6.74 (1 H, q, J 1.6 Hz), 7.32 (2H, br s), 7.39 (1 H, d, J 3.6 Hz), 7.43 (1 H, s) and 7.98 (1 H, d, J 1.2 Hz); M/Z 187 (M+H)+.
The following novel nitriles were synthesised from the appropriate 4-chloropyrimidine by Method B.
2-Amino-6-(5-methyl-2-furyl)pyrimidine-4-carbonitrile
NMR δH (400 MHz, DMSO) 2.38 (3H, s), 6.37 - 6.38 (1 H, m), 7.28 (2H, s), 7.32 (1 H, d, J 3.5 Hz) and 7.37 (1 H, s) ; M/Z 201 (M+H)+
2-Amino-6-(2-thiazolyl)pyrimidine-4-carbonitrile IR vmax (DR)/cnf1 3457, 3325, 3223, 3110, 2246, 1646, 1572, 1435, 1388, 1348 and 1241 ; NMR δH (400 MHz, DMSO) 7.57 (2H, br s), 7.62 (1 H, s), 8.07 (1 H, d, J 3.1 Hz) and 8.12 (1 H, d, J 3.0 Hz) Method C 2-Amino-6-(2-furyl)pyrimidine-4-carboxylic acid A suspension of 2-amino-6-(2-furyl)pyrimidine-4-carbonitrile (7.06 g, 37.9 mmol) in water (30 mL) was treated carefully with concentrated sulfuric acid (30 mL), stirred at 100 SC for 5 2 h, allowed to cool to room temperature and poured onto a mixture of ice (150 g) and water (150 mL). After standing for 1 h the crude product was filtered off, washed with water and MeCN, and dried in air to give the title compound (7.02 g, 90 %) as a brown solid; NMR δH (400 MHz, DMSO) 6.71 (1 H, dd, 1.6, 3.6 Hz), 7.04 (2H, br s), 7.30 (1 H, d, J 3.6 Hz), 7.36 (1 H, s) and 7.94 (1 H, d, J 1.2 Hz); Anal. Calc for C9H7N303 . 1.6 H20: C, 10 46.20; H, 4.39; N, 17.96. Found: C, 46.22; H, 4.22; N, 17.82.
The following novel carboxylic acids were synthesised from the appropriate pyrimidine-4- carbonitrile by Method C.
15 2-Amino-6-(5-methyl-2-furyl)pyrimidine-4-carboxylic acid NMR δH (400 MHz, DMSO) 2.38 (3H, s), 6.33 - 6.34 (1 H, m), 6.97 (2H, s), 7.21 (1 H, d, J 3.0 Hz), 7.30 (1 H, s) and 13.12 (1 H, s); M/Z 220 (M+H)+
2-Amino-6-(2-thiazolyl)pyrimidine-4-carboxylic acid
20 IR vmax (DR)/cm-1 3125 br, 1748, 1673, 1625, 1481 , 1427, 1356 and 1275; NMR δH (400 MHz, DMSO) 7.69 (1 H, s), 8.01 (1 H, d, J3.1 Hz), 8.09 (1 H, d, 3.2 Hz); M/Z 223 (M+H)+
2- Am i no-6-(4- met hy It hiazol-2-y l)pyri m id ine-4-carboxy I i c acid IR vmax (DR)/cm-1 3418, 3333, 3225, 1656, 1589, 1515, 1451 , 1352 and 1225; NMR δH 25 (400 MHz, DMSO) 2.46 (3H, s), 7.21 (2H, br s), 7.56 (1 H, s) and 7.65 (1 H, s); M/Z 237 (M+H)+
Method D 2-Amino-6-(2-furyl)-/V-(3-methylpyridin-2-yl)methylpyrimidine-4-carboxamide 30 (Example 11) A suspension of 2-amino-6-(2-furyl)pyrimidine-4-carboxylic acid (206 mg, 1.0 mmol) in DMF (5 mL) was treated with N,N'-carbonyldiimidazole (162 mg, 1.0 mmol), stirred for 2 h, treated with 3-methylpyridine-2-methanamine (244 mg, 2.0 mmol), stirred for 2 h, poured onto water (50 mL) and extracted with EtOAc (2 x 25 mL). The extracts were washed with 5 water, concentrated in vacuo, and the crude product was triturated with ether to give the title compound (109 mg, 35 %) as a yellow solid. Method E 2-[(6-MethoxymethyI)pyridin-2-yl]methylisoindole-1,3(2H)-dione
A solution of 2-[(6-hydroxymethyl)pyridin-2-yl]methylisoindole-1 ,3(2/-)-dione (4.02 g, 15.0 mmol) in DMF (20 mL) at 0 QC was treated with NaH (60% dispersion in mineral oil, 600 mg, 15.0 mmol), stirred for 15 min at 0 SC, treated with methyl iodide (1.03 ml, 16.5 mmol), warmed to room temperature and stirred for 2 days. The reaction mixture was poured onto water (100 mL), extracted with EtOAc (3 x 100 mL), dried (MgS04), concentrated in vacuo and purified by chromatography [Si02; isohexane:EtOAc (1 :4)] to give the title compound (1.11 g, 26 %) as a white solid; NMR δH (400 MHz, CDCI3) 3.42 (3H, s), 4.51 (2H, s), 5.01 (2H, s), 7.10 (1 H, d, J 8.0 Hz), 7.30 (1 H, d, J 8.0 Hz), 7.63 (1 H, t, 7.5 Hz), 7.73 - 7.76 (2H, m) and 7.87 - 7.91 (2H, m); Rf (EtOAc) = 0.77.
Method F 6-Methoxymethylpyridine-2-methanamine
A solution of 2-[(6-methoxymethyl)pyridin-2-yl]methylisoindole-1,3(2/-/)-dione (1.11 g, 3.94 mmol) in EtOH (75 mL) was treated with hydrazine hydrate (0.95 mL, 19.5 mmol), stirred at 80 SC overnight, cooled to room temperature, filtered through Celite and concentrated in vacuo to give the title compound (265 mg, 44 %) as a yellow oil; NMR δH (400 MHz, CDCIg) 2.10 (2H, br s), 3.48 (3H, s), 3.97 (2H, s), 4.57 (2H, s), 7.18 (1 H, d, J8.0 Hz), 7.28 (1 H, d, J 8.0 Hz) and 7.66 (1 H, t, J 7.5 Hz).
Method G 3-Methoxymethylpyridine-2-carbonitrile A stirred solution of 3-bromomethylpyridine-2-carbonitrile (591 mg, 3.0 mmol) in MeOH (10 mL) at 0 SC was treated with NaOMe (324 mg, 6.0 mmol), warmed to room temperature, stirred for 2 h, concentrated in vacuo and partitioned between EtOAc (50 mL) and water (30 mL). The organic phase was dried (MgS04), concentrated in vacuo and purified by chromatography [Si02; hexane:EtOAc (9:1 - 4:1)] to give the title compound (297 mg, 67 %) as a clear oil; NMR δH (400 MHz, CDCI3) 3.51 (3H, s), 4.68 (2H, s), 7.50 - 7.55 (1 H, m), 7.92 - 7.96 (1H, m) and 8.63 (1 H, dd, 5.0, 1.5 Hz); Rf [isohexane:EtOAc (4:1)] = 0.65.
The following novel nitriles were synthesised from 6-bromomethyl-3-methylpyridine-2- carbonitrile by Method G. 6-Methoxymethyl-3-methylpyridine-2-carbonitrile
NMR δH (400 MHz, CDCI3) 2.55 (3H, s), 3.47 (3H, s), 4.56 (2H, s), 7.56 (1 H, d, J 8.0 Hz) and 7.67 (1H, d, 8.5 Hz); HPLC 1.6 min. (20/50).
6-Cyclopropylmethoxymethyl-3-methylpyridine-2-carbonitrile
NMR δH (400 MHz, CDCI3) 0.24 - 0.28 (2H, m), 0.56 - 0.61 (2H, m), 1.09 - 1.18 (1 H, m), 2.57 (3H, s), 3.42 (2H, d, 7.0 Hz), 4.66 (2H, s), 7.63 (1H, d, 8.0 Hz) and 7.68 (1 H, d, J 8.0 Hz); HPLC 1.2 min. (50/80).
Method H
3-( , /-Dimethylamino)methylpyridine-2-carbonitrile
A solution of 3-bromomethylpyridine-2-carbonitrile (591 mg, 3.0 mmol) in MeCN (10 mL) was treated with dimethylamine (7.9-M in water, 1.9 mL, 15 mmol) and heated at 50 SC for 4 h. The solution was treated with MP-carbonate (2.0 g, 6.0 mmol), stirred for 30 min, filtered through Celite and the residue was washed with EtOAc. The filtrate was concentrated in vacuo, and the crude product was purified by chromatography [Si02; MeOH: EtOAc: isohexane (0:4:1 - 1 :9:0)] to give the title compound (541 mg, 96 %) as an orange oil; NMR δH (400 MHz, CDCI3) 2.31 (6H, s), 3.67 (2H, s), 7.50 (1 H, dd, J 8.0, 4.5 Hz), 7.94 (1 H, dd, 8.0, 1.5 Hz) and 8.61 (1 H, dd, J4.5, 1.5 Hz); M/Z 162 (M+H)+.
The following novel compound was synthesised from 3-bromomethylpyridine-2- carbonitrile and morpholine by Method H.
3-(4-Morpholinyl)methylpyridine-2-carbonitrile NMR δH (400 MHz, CDCI3) 2.50 - 2.55 (4H, m), 3.68 - 3.74 (6H, m), 7.50 (1 H, dd, J 8.0, 5.0 Hz), 7.92 - 7.95 (1 H, m) and 8.62 (1 H, dd, 4.5, 1.5 Hz); M/Z 204 (M+H)+.
Method I 3,6-Dimethylpyridine-2-methanamine A solution of 3,6-dimethylpyridine-2-carbonitrile (264 mg, 2.00 mmol) in EtOH (10 mL) was treated with Raney-Ni (approximately 100 mg) and stirred under an atmosphere of hydrogen for 4 h at room temperature. The mixture was filtered through Celite and concentrated in vacuo to give the title compound (270 mg, 99 %) as a yellow oil; NMR δH (400 MHz, CDCI3) 2.31 (3H, s), 2.51 (3H, s), 4.17 (2H, s), 7.00 (1 H, d, 7.5 Hz) and 7.37 (1 H, d, J 7.5 Hz); M/Z 137(M+H)+. The following novel amines were also synthesised by Method I from the appropriate nitrile.
3-Methoxymethylpyridine-2-methanamine M/Z 153 (M+H)+.
3-(Λ.,ΛADimethylamino)methylpyridine-2-methanamine
M/Z 166 (M+H)+.
3-(4-Morpholinyl)methylpyridine-2-methanamine NMR δH (400 MHz, CDCI3) 2.41 - 2.47 (4H, m), 3.50 (2H, s), 3.68 (4H, t, J 4.5 Hz), 4.02 (2H, s), 7.14 (1 H, dd, 7.5, 4.5 Hz), 7.54 (1 H, dd, 7.5, 1.5 Hz) and 8.49 (1 H, dd, 5.0, 1.5 Hz); M/Z 208 (M+H)+.
2-Dimethylamino-6-methylpyridine-3-methanamine NMR δH (400 MHz, CDCI3) 1.79 (2H, s), 2.45 (3H, s), 2.85 (6H, s), 3.96 (2H, s), 6.74 (1 H, d, J7.5 Hz) and 7.46 (1H, d, 7.5 Hz).
6-Methoxymethyl-3-methylpyridine-2-methanamine
NMR δH (400 MHz, CDCI3) 1.74 (2H, s), 2.28 (3H, s), 3.47 (3H, s), 3.94 (2H, s), 4.55 (2H, s), 7.18 - 7.20 (1 H, m) and 7.41 - 7.44 (1 H, m); M/Z 167 (M+H)+
6-Cyclopropylmethoxymethyl-3-methylpyridine-2-methanamine
NMR δH (400 MHz, CDCI3) 0.22 - 0.28 (2H, m), 0.54 - 0.61 (2H, m), 1.08 - 1.19 (1 H, m), 1.76 (2H, s), 2.30 (3H, s), 3.41 - 3.43 (2H, m), 3.96 (2H, s), 4.65 (2H, d, J 4.0 Hz), 7.25 - 7.27 (1 H, m) and 7.42 - 7.45 (1 H, m); HPLC 0.73 min. (20/50).
3-Aminomethyl-N,N-dimethylbenzamide
NMR δH (400 MHz, DMSO) 1.92 - 3.54 (2H, s), 2.94 (6H, d, 26.0 Hz), 3.71 (2H, s) and 7.05 - 7.48 (4H, m)
1-(2-(Trimethylsilyl)ethoxy)methyl-1 H-imidazole-2-methanamine dihydrochloride
NMR δH (400 MHz, DMSO) 0.00 (9H, s), 0.93 - 0.89 (2H, m), 3.55 - 3.59 (2H, m), 4.40 (2H, s), 5.64 (2H, s), 7.57 (1H, s), 7.75 (1 H, s) and 8.94 (2H, br s); M/Z 228 (M+H)+ N-(6-Aminomethyl-5-methylpyridine-2-ylmethyl)-N-methyIacetamide
NMR δH (400 MHz, DMSO) (1 :1 mixture of rotamers) 2.16 (1.5H, s), 2.17 (1.5H, s), 2.25 (1.5H, s), 2.27 (1.5H, s), 2.98 (1.5H, s), 3.07 (1.5H, s), 3.92 (1 H, s), 3.94 (1 H, s), 4.58 (1 H, s), 4.67 (1 H, s), 6.93 (0.5H, d, 7.5 Hz), 7.03 (0.5H, d, J7.5 Hz), 7.37 (0.5H, d, 7.5 Hz) and 7.42 (0.5H, d, J 7.5 Hz); M/Z 208 (M+H)+
6-(lsopropoxymethyl)pyridine-2-methanamine
NMR δH (400 MHz, CDCI3) 1.17 (6H, br m), 3.70 (1 H, m), 3.80 (2H, br m), 4.50 (2H, s), 7.20 - 7.40 (2H, m) and 7.70 - 7.80 (1 H, m); M/Z 183 (M+H)+
6-n-Propylpyridine-2-methanamine
NMR δH (400 MHz, CDCI3) 0.92 (3H, m), 1.76 (2H, m), 2.94 (2H, m), 4.38 (2H, m), 7.65
(1 H, d, 8.0 Hz), 7.83 (1H, d, 8.0 Hz), 8.22 (1 H, t, 8.0 Hz) and 8.95 (2H, br s)
1 -Methyl-1 W-pyrazole-5-methanamine
NMR δH (400 MHz, DMSO) 3.80 (3H, s), 3.99 (2H, s), 6.09 (2H, s), 6.27 (1 H, d, J 1.5 Hz) and 7.35 (1 H, d, J 1.5 Hz)
Method J 2-Amino-6-(2-furyl)- V-(5-indolylmethyl)pyrimidine-4-carboxamide (Example 35)
A mixture consisting of 2-amino-6-(2-furyl)pyrimidine-4-carboxylic acid (206 mg, 1.0 mmol), indole-5-methanamine (146 mg, 1.0 mmol), polymer supported carbodiimide (Argonaut Technologies, loading 1.38 mmol/g, 1 .1 Og, 1.5 mmol) and 1- hydroxybenzotriazole hydrate (203 mg, 1.5 mmol) in DMF (5 mL) was stirred at room temperature for 24 hr. The mixture was filtered through a pad of Celite, washing through with EtOAc. The filtrate was washed successively with H20 (10 mL), 2-M Na2C03 (2 x 10 mL) and H20 (10 mL), dried (MgS04) and concentrated in vacuo. The resulting oil was dissolved in MeOH (1.0 mL), added dropwise with stirring to H20 (2 mL) and the resulting precipitate filtered to give the title compound (198 mg, 59 %) as a cream solid.
Method K
2-Amino-Λ -benzyl-6-(2-furyl)pyrimidine-4-carboxamide (Example 42)
A solution of 2-amino-6-(2-furyl)pyrimidine-4-carboxylic acid (103 mg, 0.5 mmol) in DMF
(2 mL) was treated with benzylamine (59 mg, 0.55 mmol), EDCI (104 mg, 0.54 mmol) and 4-dimethylaminopyridine (66 mg, 0.54 mmol), stirred at room temperature for 17 h, poured into water (25 mL) and extracted with EtOAc (2 x 25 mL). The combined organic phase was washed with water (25 mL), dried (MgS04), concentrated in vacuo and purified by chromatography [Si02; isopropyl ether:EtOAc, (100:0 - 0:100)] to give the title compound (52 mg, 40 %) as an off-white solid.
Method L
2-Bromomethyl-6-(triphenylmethoxymethyl)pyridine
A solution of 6-(triphenylmethoxymethyl)pyridine-2-methanol (16.8 g, 44 mmol) in CH2CI2 at 0 SC was treated with triphenylphosphine (17.3 g, 66 mmol) and carbon tetrabromide (17.5 g, 52.8 mmol), stirred at 0 QC for 2.5 h then concentrated in vacuo to approximately a quarter of the original volume. The resulting solution was filtered through a pad of silica, washed with hexane:EtOAc (1:1) and the filtrate concentrated in vacuo to give the title compound (16.8 g, 86 %) as a cream solid; NMR δH (400 MHz, DMSO) 4.14 (2H, s), 4.61 (2H, s), 7.27 - 7.48 (16H, m), 7.68 (1 H, d, J 7.5 Hz) and 7.90 (1 H, t, J 7.5 Hz); R, (Hexane:EtOAc (2:1))= 0.84
The following novel bromides were also synthesised by Method L from the appropriate alcohol.
6-Bromomethyl-3-methylpyridine-2-carbonitrile NMR δH (400 MHz, DMSO) 2.57 (3H, s), 4.52 (2H, s) 7.58 (1 H, d, J 8.5 Hz) and 7.68 (1 H, d, 8.5 Hz); M/Z 211 and 213 (M+H)+
Method M 2-(Azidomethyl)-6-(triphenylmethoxymethyl)pyridine A solution of 2-bromomethyl-6-(triphenylmethoxymethyl)pyridine (3.04 g, 6.84 mmol) in DMF (25 mL) was treated with sodium azide (650 mg, 10 mmol) and stirred at room temperature for 20 h. The reaction was poured into water (100 mL), extracted with EtOAc (2 x 50 mL) and the combined organic phase was washed with brine (25 mL), dried (MgS04) and concentrated in vacuo to give the product (2.75 g, 99 %) as a yellow oil; IR vmax (Film)/cm"1 3060, 2103, 1679, 1594, 1448, 1096 and 706; NMR δH (400 MHz, CDCI3) 4.36 (2H, s), 4.39 (2H, s), 7.20 - 7.33 (10H, m), 7.49 - 7.52 (6H, m) and 7.72 - 7.80 (2H, m) Method N 6-(Triphenylmethoxymethyl)pyridine-2-methanamine
A solution of 2-(azidomethyl)-6-(triphenylmethoxymethyl)pyridine (2.78 g, 6.8 mmol) in THF (25 mL) was treated with triphenylphosphine (1.96 g, 7.5 mmol), stirred at room temperature for 3 h, treated with water (184 /I, 10.2 mmol), stirred at room temperature for a further 7 days and concentrated in vacuo. The resulting oil was purified by chromatography [Si02; EtOAc:MeOH:NH3 (1 :0:0) to (9:1 :0.2)] to give the titJe compound (2.33 g, 90 %) as a yellow oil; NMR δH (400 MHz, CDCI3) 1.74 (2H, s), 3.90 (2H, s), 4.34 (2H, s), 7.14 - 7.33 (10H, m), 7.50 - 7.52 (6H, m) and 7.65 - 7.74 (2H, m); M/Z 381 (M+H)+
Method O
2-Amino-6-(2-furyl)-Λ-(6-hydroxymethylpyridin-2-ylmethyl)pyrimidine-4- carboxamide (Example 33) A solution of 2-amino-6-(2-furyl)-Λ/-(6-(triphenylmethoxymethyl)pyridin-2- ylmethyl)pyrimidine-4-carboxamide (3.41 g, 6 mmol) in MeOH (50 mL) was treated with 4- M HCI in dioxane (7.5 mL, 30 mmol), stirred at room temperature for 20 h and concentrated in vacuo. The residue was diluted with water (50 mL) basifϊed with 5-M NaOH, extracted with EtOAc (2 x 25 mL) and the combined organic phase washed with brine (25 mL), dried (MgS04) and concentrated in vacuo to give the title compound (1.19 g, 61 %) as a cream solid.
Method P
2-Amino-6-(2-furyl)-N-(1H-imidazol-2-ylmethyl)pyrimidine-4-carboxamidei (Example 91)
A solution of 2-amino-6-(2-furyl)-N-(1-(2-(trimethylsilyl)ethoxy)methyl-1 Λ--imidazol-2- ylmethyl)pyrimidine-4-carboxamide (340 mg, 0.82 mmol) in MeOH (20 L) at 0 SC was treated dropwise with cone HCI (4 mL), stirred at 80 QC for 1 h, cooled to room temperature and concentrated in vacuo. The residue was triturated with diethyl ether and the resulting dihydrochloride salt (230 mg, 78%) filtered, washed with diethyl ether, stirred with saturated aqueous NaHC03 (5 mL), filtered and washed with water to give the title compound (165 mg, 71 %) as a yellow solid. Method Q
2-Amino-6-(2-furyl)-/V-(1-methyl-1W-imidazol-2-ylmethyl)pyrimidine-4-carboxamide (Example 34)
A solution of 2-amino-6-(2-furyl)-N-(1/-/-imidazol-2-ylmethyl)pyrimidine-4-carboxamide (300 mg, 1.06 mmol) in DMF (15 mL) at room temperature was treated with NaH (44 mg, 1.11 mmol), stirred for 20 min, treated with Mel (99 μl, 1.58 mmol) and stirred at room temperature for 16 h. The mixture was poured into water (30 mL), extracted with EtOAc (3 x 10 mL) and the combined organic phase was dried (MgS04), concentrated in vacuo and purified by chromatography [Si02; EtOAc] to give the title compound (180 mg, 57 %) as a yellow solid.
Method R 6-Hydroxymethyl-3-methylpyridine-2-carbonitrile
A solution of 3,6-dimethylpyridine-2-carbonitrile (4.44 g, 30.0 mmol) and cone. H2S04 (2 drops) in acetic anhydride (30 mL) was stirred at 100 SC for 16 h, cooled to room temperature, poured into water (100 mL) and basified to pH 8 with saturated aqueous NaHC03. The mixture was extracted with EtOAc (3 x 25 mL) and the combined organic phase dried (MgS04) and concentrated in vacuo. The residue was treated with MeOH (100 mL), water (40 mL) and K2C03 (8.8 g), stirred at room temperature for 1 h, concentrated in vacuo and partitioned between EtOAc and water. The organic phase was dried (MgS04) and concentrated in vacuo to give the title compound (2.4 g, 51 %) as a yellow oil; NMR δH (400 MHz, CDCI3) 2.57 (3H, s), 4.78 (2H, s), 7.42 (1 H, d, J 8.5 Hz) and 7.67 (1 H, d, J 8.5 Hz); M/Z 149 (M+H)+
Method s
N-(6-Cyano-5-methy I pyrid i ne-2-y I methyl)-N- methyl acetamide
A solution of N-methylacetamide (416 mg, 5.69 mmol) in THF (15 mL) at room temperature was treated with NaH (228 mg, 5.69 mmol), stirred for 15 min, treated with 6- bromomethyl-3-methylpyridine-2-carbonitrile (1.0 g, 4.74 mmol), stirred for 1 6 h, poured into water (50 mL), extracted with EtOAc (3 x 15 mL) and the combined organic phase was dried (MgS0 ) and concentrated in vacuo to give the title compound (665 mg, 69 %) as a yellow oil; NMR δH (400 MHz, CDCI3) 2.15 (3H, s), 2.53 (3H, s), 3.09 (3H, s), 4.65 (2H, s), 7.43 (1H, d, J8.0 Hz) and 7.61 (1 H, d, J8.0 Hz); M/Z 204 (M+H)+ Method T
6-(2-Amino-6-(2-furyl)pyrimidine-4-carboxamidomethyl)pyridin-2-ylmethyl isopropylcarbamate (Example 41)
A solution of 2-amino-6-(2-furyl)-/V-(6-hydroxymethylpyridin-2-ylmethyl)pyrimidine-4- carboxamide (200 mg, 0.61 mmol) in DMF (10 mL) was treated with iso-propyl isocyanate
(86 μl, 0.915 mmol) and triethylamine (one drop) and shaken at 90 SC for 20 h. The incomplete reaction was treated with iso-propyl isocyanate (57 μl, 0.61 mmol) and shaken at 90 SC for a further 20 h, concentrated in vacuo and purified by preparative HPLC to give the title compound (70 mg, 28 %) as a beige solid.
Method U
6-(2-Amino-6-(2-furyl)pyrimidine-4-carboxamidomethyl)pyridin-2-ylmethyl dimethylcarbamate (Example 54)
A stirred solution of 2-amino-6-(2-furyl)-Λ/-(6-hydroxymethylpyridin-2-ylmethyl)pyrimidine- 4-carboxamide (50 mg, 0.15 mmol) in DMF (5 mL) at 0 SC was treated with NaH (6 mg,
0.15 mmol), stirred for 5 min, treated with dimethylcarbamyl chloride (14 μl, 0.15 mmol), stirred at room temperature for 1 h, diluted with water and the resulting precipitate filtered to give the title compound (35 mg, 58 %) as a cream solid.
Method V
2-Amino-ιV-(4-amino-3-methylbenzyl)-6-(2-furyl)pyrimidine-4-carboxamide hydrochloride (Example 84)
A suspension of 2-amino-6-(2-furyl)-Λ/-(3-methyl-4-nitrobenzyl)pyrimidine-4-carboxamide (101 mg, 0.29 mmol) in EtOH (3 mL) at 50 °C was treated dropwise with a freshly prepared solution of SnCI2 dihydrate (193 mg, 0.857 mmol) in concentrated HCI (0.7 mL) and heated at 70 °C for 24 h, cooled, filtered and the resulting solid washed with a little EtOH. The resulting HCI salt was slurried with 2.5-M NaOH solution, filtered and the solid dissolved in hot THF, filtered through a pad of silica, and the filtrate concentrated in vacuo to give the free base as a yellow oil. The oil was dissolved in MeOH, treated with HCI solution (4-M in dioxane, 0.5 mL), stirred for 24 h and filtered to give the title compound (31 mg, 35 %) as a grey solid. Method W
2-Amino-Λ^(6-amino-2-pyridylmethyl)-6-(2-furyl)pyrimidine-4-carboxamide (Example 95)
A mixture of 2-amino-/V-(6-bromo-2-pyridylmethyl)-6-(2-furyl)pyrimidine-4-carboxamide (350 mg, 0.93 mmol) and copper(l)oxide (6.7 mg, 0.046 mmol) in 4-M NH4OH in ethylene glycol (20.23 ml, 80.92 mmol) was heated in a sealed tube at 90 SC for 20 h, cooled, poured into water (100 mL) and extracted with EtOAc (2 x 25 mL). The combined organic phase was washed with brine (10 mL), dried (MgS04), concentrated in vacuo and purified by chromatography [Si02; Hexane:EtOAc (1 :4) - (0:1)] to give the title compound (65 mg, 22 %) as a cream solid.
Method X 2-Amino-6-(2-furyl)-5-methylpyrimidine-4-carbonitrile
A solution of 4-chloro-6-(2-furyl)-5-methylpyrimidine-2-amine (80 mg, 0.38 mmol) in acetonitrile (4 mL) was treated with polymer supported cyanide (0.636 mg, 1.91 mmol), stirred at 140 °C in the microwave for 30 min, filtered to remove the resin and the filter cake washed with acetonitrile. The filtrate was concentrated in vacuo to give the title compound (50 mg, 65 %) as off-white solid; NMR δH (400 MHz, DMSO) 2.48 (3H, s), 6.75 (1 H, dd, J 1.7, 3.5 Hz), 7.04 (2H br s), 7.28 (1 H, dd, 0.7, 3.5 Hz) and 8.00 (1 H, dd, J 0.7, 1.7 Hz); M/Z 201 (M=H)+; HPLC 1.1 min. (50/80).
Method Y 4-Hydroxy-6-(2-thiazolyl)pyrimidine-2-amine
Guanidine carbonate (3.48 g, 19.32 mmol) was suspended in EtOH (100 mL) and toluene (20 mL) and 50 mL of the solvent was distilled off using a Dean & Stark apparatus. The suspension was cooled to 40 °C, treated with a solution of ethyl β-oxo-2- thiazolepropionate (7.7 g, 38.65 mmol) in EtOH (20 mL), refluxed for 40 h, cooled, treated with water (50 mL) and refluxed for 30 min. The suspension was cooled to 0 °C, treated with a solution of cone. HCI (4 mL) in water (40 mL), stirred at 0 °C for 30 min and the resulting precipitate filtered, washed with water (2 x 25 mL) and MeCN (2 x 25 mL) and air dried to give the title compound (2.7 g, 36 %) as a yellow solid; IR vmax (DR)/cm"1 3188 br, 1664, 1609, 1460, 1437, 1376 and 1245; NMR δH (400 MHz, DMSO) 6.27 (1 H, s), 6.79 (2H, br s), 7.90 (1 H, d, J 3.2 Hz) and 7.98 (1 H, d, J 3.2 Hz)
The following novel compound was also synthesised by Method Y from ethyl 4-methyl-β- oxo-2-thiazolepropionate. 4-Hydroxy-6-(4-methylthiazol-2-yl)pyrimidine-2-amine
NMR δH (400 MHz, DMSO) 2.42 (3H, s), 6.21 (1H, s), 6.75 (2H, br s), 7.45 (1 H, s) and 10.90 (1 H, br s); M/Z 209 (M+H)+; Anal. Calc for C8H8N4OS: C, 46.14; H, 3.87; N, 26.89. Found: C, 46.04; H, 3.91 ; N, 26.53.
Method Z 4-Chloro-6-(2-thiazolyl)pyrimidine-2-amine
A suspension of the 4-hydroxy-6-(2-thiazolyl)pyrimidine-2-amine (2.64 g, 13.6 mmol) in POCI3 (30 mL) was heated at 120 °C for 3 h, cooled and concentrated in vacuo. The resulting brown solid was added to ice/water (200 g), basified with NH OH (8 mL), filtered and purified by chromatography [Si02; EtOAc : isohexane (2:3 - 1 :0)] to give the title compound (1.73 g, 60 %) as a pale yellow solid; NMR δH (400 MHz, DMSO) 7.22 (1 H, s), 7.40 (2H, br s), 8.01 (1 H, d, J3.2 Hz) and 8.07 (1 H, d, J3.2 Hz); M/Z 213, 215 (M+H)+
Method AA
Ethyl 4-methyl~β-oxo-2-thiazolepropionate
NaH (60% in oil, 1.34 g, 33.5 mmol) was washed with isohexane (2 x 14 mL), suspended in toluene (25 mL), treated with diethyl carbonate (4.7 mL, 4.6 g, 38.8 mmol), heated to 80 °C, treated dropwise over 20 min with a solution of 2-acetyl-4-methylthiazole (2.72 g, 19.2 mmol) in toluene (5 mL) and stirred at 80 °C for 2 h. The mixture was cooled to 0 °C, treated dropwise with HOAc (4.65 mL, 4.9 g, 81 mmol) followed by ice (25 g) and water (50 mL) and stirred for 30 min. The aqueous phase was extracted with toluene (50 mL), the combined organic phase was washed with water (50 mL), dried (MgS0 ) and concentrated in vacuo to give the crude product (3 g, 74 %) as a dark red oil, used in the next step without further purification; NMR δH (400 MHz, CDCI3) 1.26 (3H, t, J 7.2 Hz), 2.92 (3H, s), 4.14 (2H, s), 4.18 - 4.25 (2H, m) and 7.31 (1 H, s).
Method AB 4-Chloro-6"(5-methyl-2-furyl)pyrimidine-2-amine
A solution of 2-methylfuran (11 mL, 122 mmol) and N, N, N', N'- tetramethylethylenediamine (18.4 mL, 122 mmol) in anhydrous THF (500 mL) at -78 SC under nitrogen was treated with n-butyl lithium (48.8 mL, 122 mmol), stirred at -78 °C for 20 min, warmed to 0 SC for 30 min and then warmed to room temperature for 15 min. The reaction was cooled to -78 QC, treated with trimethyl borate (27.4 ml, 244 mmol), warmed to room temperature, treated with MeOH (100 mL) and water (5 mL), stirred at room temperature for 30 min and concentrated in vacuo. The residue was treated with MeOH (3 x 100 mL) and concentrated in vacuo after each addition to give the boronic ester as an orange gum. A solution of 2-amino-4,6-dichloropyrimidine (20 g, 1 22 mmol) in THF (1 L) was treated with saturated aqueous NaHC03 (250 mL), a solution of the above boronic ester (122 mmol) in THF (50 mL) and tetrakis(triphenylphosphin«3)palladium (6.93 g, 6 mmol), stirred at 70 QC for 20 h, cooled, extracted with EtOAc (2 x 100 mL), washed with water (200 mL) and the combined organic phase dried (MgSO_ι.) and concentrated in vacuo to give the product (24.5 g, 96 %) as a yellow solid; NMR δH (400 MHz, DMSO) 2.37 (3H, s), 6.32 - 6.33 (1 H, m), 6.89 (1 H, s), 7.11 (2H, s) and 7.1 S - 7.19 (1 H, m).
Method AC
6-(Tert-bu.yldimethylsilyloxymethyl)pyridine-2-methanamine
A solution of 6-aminomethypyridine-2-methanol (5 g, 36.2 mmol) in anhydrous DMF (25 mL) at 0 SC was treated with ferf-butyldimethylsilyl chloride (5.728 g, 38 mmol) and imidazole (2.584g, 38 mmol), stirred at room temperature for 20 h, poured into 1.5-M aqueous NaOH (100 mL) and extracted with EtOAc (3 x 20 mL). The combined organic phase was washed with water (4 x 10 mL), brine (2 x 20 ml_ ), dried (MgS04) and concentrated in vacuo to give the title compound as a yellow o il; NMR δH (400 MHz, CDCI3) 0.82 (9H, s), 0.87 (6H, s), 1.81 (2H, s), 3.84 (2H, s), 4.73 (2H, s), 7.03 (1 H, d, J 8.0 Hz), 7.28 (1 H, d, 7.5 Hz) and 7.57 (1 H, t, J 8.0 Hz); M/Z 253 (M+H)+
Method AD
2-Amino-6-(5-methyl-2-furyl)-Λf-(6-hydroxymethylpyridin-2-ylmethyl)pyrimidine-4- carboxamide (Example 133) A solution of 2-amino-6-(5-methyl-2-furyl)-Λ/-(6-(tert-butyldimethyls ilyloxymethyl)pyridin-2- ylmethyl)pyrimidine-4-carboxamide (614 mg, 1.36 mmol) in acetic acid (9 mL) water (3 mL) and THF (3 mL) was stirred at room temperature for 4 days, neutralised with saturated aqueous NaHC03 and extracted with EtOAc. The combined organic phase was dried (MgS04), concentrated in vacuo, and the resulting solid triturated with MeOH and filtered to give the title compound (536 mg, 49 %) as a cream solid.
Method AE
2-Amino-5-chloro-Λ-(6-methoxymethyl-2-pyridylmethyl)-6-(5-methyl-2- furyl)pyrimidine-4-carboxamide (Example 116) A solution of 2-amino- -(6-methoxymethyl-2-pyridylmethyl)-6-(5-methyl-2-furyl)pyrimidine- 4-carboxamide (50 mg, 0.142 mmol) in acetic acid (10 L) at room temperature was treated with N-chlorosuccinimide (24 mg, 0.156 mmol), stirred at 100 SC for 2 h, cooled to room temperature, concentrated in vacuo and partitioned between EtOAc (20 mL) and saturated aqueous NaHC03 (20 mL) .The organic phase was dried (MgS04), concentrated in vacuo and the resulting solid was triturated with diethyl ether and filtered to give the title compound (30 mg, 54 %) as a beige solid.
Method AF
2-Amino-5-bromo- < (6-methoxymethyl-2-pyridylmethyl)-6-(5-methyl-2- furyl)pyrimidine-4-carboxamide (Example 117) A solution of 2-amino-Λ/-(6-methoxymethyl-2-pyridylmethyl)-6-(5-methyl-2-furyl)pyrimidine- 4-carboxamide (50 mg, 0.142 mmol) in acetic acid (10 mL) at room temperature was treated with N-bromosuccinimide (28 mg, 0.156 mmol), stirred for 2 h, concentrated in vacuo and partitioned between EtOAc (20 mL) and saturated aqueous NaHC03 (20 mL) .The organic phase was dried (MgS04), concentrated in vacuo and the resulting solid was triturated with diethyl ether and filtered to give the title compound (50 mg, 82 %) as a beige solid.
Method AG 2-(lsopropoxymethyl)pyridine-N-oxide A stirred solution of 2-isopropoxymethylpyridine (18.4 g, 0.121 mol) in dichloromethane (200 mL) at room temperature was treated portionwise with mefø-chloroperoxybenzoic acid (42.1 g, 0.121 mol), stirred for 3 h, poured into CHCI3 (450 mL) and washed with 2.5- M aqueous NaOH solution (2 x 250 mL). The organic phase was dried (MgS0 ) and concentrated in vacuo to give the title compound as a pale yellow oil; NMR δH (400 MHz, CDCI3), 1.19 - 1.21 (6H, d, 6 Hz), 3.71 - 3.80 (1H, sept, J6.5 Hz), 4.58 (2H, s), 7.37 (2H, m), 7.47 - 7.49 (1 H, d, J7 Hz) and 8.25 - 8.27 (1H, d, J7.5 Hz)
Method AH
6-(lsopropoxy met hyl)pyridine-2-carbonit rile A stirred solution of 2-(isopropoxymethyl)pyridine-N-oxide (17.8 g, 0.11 mol) in dichloromethane (200 mL) at room temperature was treated with trimethylsilyl cyanide (17.65 mL, 0.132 mol) and dimethylcarbamyl chloride (12.18 mL, 0.132 mol), heated to 40 °C for 18 h, quenched with 2-M aqueous Na2C03 solution (400 mL) and stirred for 2 h. The mixture was extracted with dichloromethane (2 x 200 mL), dried (MgS04) and concentrated in vacuo to give the title compound as an orange oil; NMR δH (400 MHz, CDCIg) 1.17 - 1.18 (6H, d, J 6 Hz), 3.67 - 3.76 (1H, sept J 6 Hz), 4.58 (2H, s), 7.74 - 7.76 (1 H, d, J 8 Hz), 7.92 -7.94 (1 H, d, J 7.5 Hz) and 8.04 - 8.08 (1 H, t, J 7.5 Hz)
Method Al 4-Chloro-N-methyl-6-(5-methylfuran-2-yl)pyrimidine-2-amine
A solution of 2,4-dichloro-6-(5-methylfuran-2-yl)pyrimidine (0.70 g, 3.07 mmol) in MeOH (5 mL) was treated with 2-M methylamine in EtOH (2 mL, 4 mmol), heated at 80 °C for 30 min, cooled, concentrated in vacuo and purified by chromatography [Si02; hexane:EtOAc (100:0 - 90:10)] to give the title compound (0.17 g, 22 %) as a white solid; NMR δH (400 MHz, CD3OD) 2.38 (3 H, s), 2.93 (3 H, s), 6.22 - 6.23 (1 H, m), 6.83 (1 H, s) and 7.12 - 7.13 (1 H, m); M/Z 224, 226 (M+H)+
Method AJ
2-Dimethylamino-6(5-methylfuran-2-yl)pyrimidine-4-carboxylic acid lithium salt A mixture of 2-dimethylamino-6-(5-methylfuran-2-yl)pyrimidine-4-carbonitrile (0.68 g, 2.98 mmol) in 6-M HCI (40 mL) and THF (10 mL) was refluxed for 6 h, cooled, concentrated in vacuo and the residue subjected to ion-exchange column chromatography (Isolute® Flash SCX-2; DCM;MeOH then 1-M NH3:MeOH). The resulting mixture of methyl ester and carboxylic acid (0.42 g) was treated with MeOH (15 mL), water (15 mL) and LiOH (72 mg, 1.81 mmol), stirred at room temperature for 1 h and concentrated in vacuo to give the title compound (0.48 g, 98 %) as a white solid: NMR δH (400 MHz, CD3OD) 2.38 (3H, s), 3.23 (6H, s), 6.19 - 6.20 (1 H, m), 7.08 - 7.09 (1 H, m) and 7.31 (1 H, s); M/Z 248 (M+H)+
Method AK 2-Amino-6-phenylpyrimidine-4-carboxylic acid
A solution of methyl 2-amino-6-chloropyrimidine-4-carboxylate (0.2 g, 1.07 mmol) and phenylboronic acid (0.16 g, 1.3 mmol) in THF (10 mL) was treated with saturated aqueous
NaHC03 (1.6 mL). Nitrogen was bubbled through the solution for 5 min then tetrakis(triphenylphosphine)palladium(0) (0.04 g) was added and the mixture refluxed under nitrogen overnight. The mixture was treated with aqueous LiOH (1-M, 1 mL), heated at 90 °C for 2 h, concentrated in vacuo and partitioned between ethyl acetate and water. The aqueous layer was acidified to pH 1 with 2-N HCI, the resulting suspension centrifuged, the liquors decanted and the resulting solid dried to give the title compound (0.17 g, 72 %) as a white powder which was used directly in the next step without further purification; M/Z 216 (M+H)+; retention time 1.60 min (Method AM). The following novel intermediates were also synthesized by Method AK from methyl 2- amino-6-chloropyrimidine-4-carboxylate and the appropriate arylboronic acid.
2-Amino-6-(2-methylphenyl)pyrimidine-4-carboxylic acid M/Z 230 (M+H)+; retention time 1.69 min (Method AM).
2-Amino-6-(3-methylphenyl)pyrimidine-4-carboxylic acid
M/Z 230 (M+H)+; retention time 1.77 min (Method AM).
2-Amino-6-(4-methylphenyl)pyrimidine-4-carboxylic acid
M/Z 230 (M+H)+; retention time 1.75 min (Method AM).
2-Amino-6-(3-methoxyphenyl)pyrimidine-4-carboxylic acid
M/Z 246 (M+H)+; retention time 1.69 min (Method AM).
2-Amino-6-(3-cyanophenyl)pyrimidine-4-carboxylic acid
M/Z 241 (M+H)+; retention time 1.64 min (Method AM).
Method AL General method for preparative LC-MS
Preparative LC-MS was performed at ambient temperature on a Waters FractionLynx MS autopurification system using a Luna 5 μm, C18(2), 100 mm x 21.2 mm i.d. column from Phenomenex. Solvent A: water + 0.08% v/v formic acid, solvent B: 95% methanol-water + 0.08% v/v formic acid, flow rate: 20 ml min-1. The instrument incorporated a photo diode array detector (210-400 nm) and a MicroMass ZQ mass spectrometer. The ionisation method was positive ion electrospray and the molecular weight scan range was 150- 1000. Collection was triggered by detection of the selected mass ion.
Method AM General method for analytical LC-MS
HPLC: HP1100
Column: Luna 3μm, C18(2), 30mm x 4.6mm i.d. from Phenomenex
Temperature: 22°C
Solvents: A - Water + 10mmol NH4OAc + 0.08% (v/v) formic acid B - 95% Acetonitrile / 5% Solvent A + 0.08% (v/v) formic acid
Flow rate: 2ml/min Gradient Total acquisition time is 3.75minutes
Figure imgf000061_0001
Detection: UV detection at 230nm, 254nm and 270nm
Mass Spec: HP1100 MSD, Series A Ionisation is positive or negative ion electrospray Molecular weight scan range is 120-1000
Results for observed molecular ions and HPLC retention times are given.
Method AN General method for analytical HPLC
HPLC is carried out using the following conditions: Column. Waters Xterra RP 18 (50 x 4.6 mm); Particle size 5 μM; Mobile phase MeOH : 10 mM aq NH4OAc (pH 7 buffer); Gradient 50:50 isocratic for 1 min. then linear gradient 50:50 to 80:20 over 5 min. then 80:20 isocratic for 3 min.; Flow rate 2.0 ml_/min.; Detection wavelength λ = 230 nM. Retention times are provided in Table 2.
Alternatively HPLC is carried out using the following conditions: Column. Supelcosil ABZ+ (170 x 4.6 mm), particle size 5 μM, mobile phase MeOH : 10 mM aq NH4OAc (80:20), (80:50), (70:30), (60:40) or (50:20) (specified in Table 2), flow rate 1.0 mlJmin., detection wavelength λ = 230 nM. Retention times and mobile phase ratio are provided in Table 2.
Method AO
General method for analytical TLC
Analytical tic. Is carried out using Merck TLC glass plates coated with silica gel 60 F254. Rf values are quoted relative to the solvent front for the given solvent.
Table 2
Figure imgf000062_0001
Figure imgf000063_0001
Mp 151.1 - 152.2 °C; IR vmax (DR)/cnrϊ13377, 3201, 2918, 1681, 1519, 1355 and 1221; NMR δH (400 MHz, DMSO) 2.31 (3H, s), 4.49 (2H, d, J 46 6.0 Hz), 6.70 - 6.72 (1H, m), 6.91 (2H, s), 7.14 - 7.21 (3H, m), 7.22 - 7.27 (1H, m), 7.30 (1H, d, 3.5 Hz), 7.42 (1H, s), 7.93-7.95 (1H, m) and 8.59 (1H, t, 6.0 Hz); LC 3.8 min. (50/80) Mp 170.6 - 170.7 °C; IR vmax (DR)/cιτϊ13487, 3316, 2919, 1633, 1520 and 1333; NMR δH (400 MHz, DMSO) 4.57 (2H, d, J 6.0 Hz), 6.70 - 50 6.72 (1H, m), 6.87 (2H, s), 7.30 (1H, dd, J 3.5, 1.0 Hz), 7.41 (1H, s), 7.55 - 7.66 (3H, m), 7.69 (1 H, s), 7.93 - 7.95 (1 H, m) and 9.04 (1 H, t, J 6.5 Hz); LC 4.9 min. (50/80) Mp 290.9 - 291.3 °C; IR vmax (DR)/cm'13425, 3277, 1671, 1599, 1510, 1459, 1323 and 1202; NMR δH (400 MHz, DMSO) 4.74 (2H, d, J 6.0
D 38 Hz), 6.70-6.74 (1H, m), 6.95 (2H, s), 7.11 -7.19 (2H, m), 7.31 (1H, d, J 3.5 Hz), 7.42 - 7.60 (3H, m), 7.95 (1 H, d, J 1.5 Hz), 8.92 (1 H, t, J 6.0 Hz) and 12.30 (1 H, s); LC 1.8 min. (50/80) Mp 162.0 - 170.0 SC; IR vmax (DR)/cm_13197, 2216, 1633, 1513, 1352 and 1219; NMR δH (400 MHz, DMSO) 4.51 (2H, d, J 6.5 Hz), 6.69 -
D 35 6.73 (1H, m), 6.86 (2H, s), 7.29 (1H, d, J3.0 Hz), 7.36 (1H, dd, 7.5, 4.5 Hz), 7.40 (1H, s), 7.73 (1H, d, 7.5 Hz), 7.94 (1H, s), 8.47 (1H, d, J 4.0 Hz), 8.56 (1H, s) and 8.98 (1H, t, 6.0 Hz); LC 5.3 min. (20/50) Mp 143.2 - 143.7 °C; IR vmax (DR)/cm'13324, 3210, 2922, 1673, 1633, 1520, 1342 and 1249; NMR δH (400 MHz, DMSO) 2.29 (3H, s), 4.45 13 (2H, d, J 6.0 Hz), 6.68 - 6.74 (1H, m), 6.88 (2H, s), 7.04 - 7.17 (3H, m), 7.22 (1H, t, J7.5 Hz), 7.29 (1H, d, 3.0 Hz), 7.42 (1H, s), 7.94 (1H, s) and 8.76 (1 H, t, J6.0 Hz); LC 3.9 min. (50/80) NMR δH (400 MHz, DMSO) 3.36 (3H, s), 4.56 (2H, s), 4.67 (2H, d, 5.5 Hz), 6.70-6.73 (1H, m), 6.99 (2H, s), 7.30 (1H, dd, J3.5, 1.0 Hz), 7.36
D 14 (1 H, dd, J 7.5, 5.0 Hz), 7.45 (1 H, s), 7.79 (1 H, dd, J 7.5, 1.5 Hz), 7.93 - 7.95 (1H, m), 8.52 (1H, dd, J 4.5, 2.0 Hz) and 8.99 (1H, t, J 5.0 Hz); M/Z 340 (M+H)+; LC 1.2 min. (50/80) IR vmax (DR)/cm_13509, 3346, 2814, 2764, 1667, 1589, 1503, 1338 and 1239; NMR δH (400 MHz, DMSO) 2.19 (6H, s), 3.49 (2H, s), 4.75 (2H,
D d, 5.5 Hz), 6.70-6.72 (1H, m), 6.94 (2H, s), 7.29 (1H, d, J 3.5 Hz), 7.33 (1H, dd, 7.0, 4.5 Hz), 7.44 (1H, s), 7.70 (1H, d, 7.0 Hz), 7.93- 7.96 (1H, m), 8.49 (1H, d, J3.5 Hz) and 9.20 (1H, t, 5.0 Hz); LC 1.1
Figure imgf000065_0001
Figure imgf000066_0001
(1H, m) and 8.64 (1H, br t, J 5.5 Hz); M/Z 299 (M+H)+; LC 3.7 min. (20/50)
Mp 170.1 - 170.5 °C; IR vmax (DR)/crτϊ13491, 3299, 1627, 1519, 1238 and 771; NMR δH (400 MHz, DMSO) 4.55 (2H, d, J6.0 Hz) 6.37 - 6.41 (1H, m), 6.71 (1H, dd, J 3.5, 1.5 Hz), 6.89 (2H, br s), 7.08 (1H, dd, J
59 8.5, 1.5 Hz), 7.29 (1H, d, 3.5 Hz), 7.32 (1H, t, J3.0 Hz), 7.35 (1H, d, J 8.5 Hz), 7.43 (1H, s), 7.49 - 7.52 (1H, m), 7.93 - 7.95 (1H, m), 8.59 (1H, t, J 6.0 Hz) and 11.04 (1 H, br s); M/Z 334 (M+H)+; LC 2.7 min. (50/80) Mp 155.9 - 156.0 °C; IR vmax (DR)/cm"13325, 2917, 1594, 1517, 1237 and 747; NMR δH (400 MHz, DMSO) 2.13 (3H, s) 2.29 (3H, s), 4.53 (3H, s), 6.71 (1H, dd, 3.5, 2.0 Hz), 6.90 (2H, brs), 6.98 (1H, dd, J8.5,
54 2.0 Hz), 7.18 (1H, d, 8.5 Hz), 7.29 (1H, d, J3.5 Hz), 7.33 (1H, brs), 7.43 (1H, s), 7.92 - 7.95 (1H, m), 8.52 (1H, t, J6.0 Hz) and 10.61 (1H, br s); M/Z 362 (M+H)+; LC 4.9 min. (50/80) Mp 191.8 - 192.2 °C; NMR δH (400 MHz, DMSO) 3.30 (3H, s) 4.55 (2H, d, 6.0 Hz), 6.71 (1H, dd, 3.5, 1.5 Hz), 6.87 (2H, brs), 7.30 (1H, d, J
33 3.5 Hz), 7.37 (1H, dd, J8.5, 1.5 Hz), 7.41 (1H, s), 7.42 (1H, brs), 7.94 (1H, d, 2.5 Hz), 7.97 (1H, d, 8.5 Hz) and 9.04 (1H, t, J6.5 Hz); M/Z 354 (M+H)+; LC 3.8 min. (50/80) NMR δH (400 MHz, DMSO) 2:1 mixture of rotamers 2.06 (1H, s), 2.18 (2H, s), 2.29 (1H, s), 2.30 (2H, s), 2.88 (2H, s), 2.96 (1H, s), 4.57 (0.66H, d, 4.5 Hz), 4.60 (1.33H, d, J 4.5 Hz), 4.63 (0.66H, s), 4.70 (1.33H, s), 6.71 - 6.72 (1H, m), 7.00 (0.66H, br s), 7.09 (1.33H, br s), 7.14 (0.33H, d, J7.5 Hz), 7.24 (0.66H, d, J7.5 Hz), 7.31 - 7.32 (1H, m), 7.45 (0.33H, s), 7.46 (0.66H, s), 7.61 (0.33H, d, J 7.5 Hz), 7.66 (0.66H, d, J7.5 Hz), 7.94 - 7.95 (1H, m), 9.34 (0.66H, br t, 4.5 Hz) and 9.37 (0.33H, br t, 4.5 Hz); M/Z 395 (M+H)+; LC 2.0 min. (50/80) NMR δH (400 MHz, DMSO) 1:1 mixture of rotamers 2.89 (1.5H, s), 2.98 - 3.05 (3.5H, m), 3.65 (1H, t, J 7.5 Hz), 3.76 (1H, t, J 7.5 Hz), 6.46 (0.5H, s), 6.69 - 6.71 (1H, m), 6.83 (0.5H, s), 6.89 (1H, s), 6.93 (1H, s), 7.12 - 7.15 (0.5H, m), 7.18 - 7.20 (1H, m), 7.24 - 7.29 (1H, m), 7.35 - 7.39 (0.5H, m), 7.63 (0.5H, dt, J7.5, 1.5 Hz), 7.75 (0.5H, dt, J7.5, 1.5 Hz), 7.92 - 7.94 (1H, m), 8.31 - 8.33 (0.5H, m) and 8.52 - 8.54 (0.5H, m); M/Z 324 (M+H)+; LC 2.3 min. (20/50)
Figure imgf000068_0001
Figure imgf000069_0001
Figure imgf000070_0001
Figure imgf000071_0001
Figure imgf000072_0001
Figure imgf000073_0001
Figure imgf000074_0001
Figure imgf000075_0001
Figure imgf000076_0001
Figure imgf000077_0001
Figure imgf000078_0001
Figure imgf000079_0001
Figure imgf000080_0001
Figure imgf000081_0001
Figure imgf000082_0001
Figure imgf000083_0001
Figure imgf000084_0001
NMR δH (400 MHz, CDCI3) 2.25 (3H, s), 2.45 (3H, s), 3.77 (3H, s), 4.87 (2H, d, J5.7 Hz), 6.04 (1H, s), 6.22 (1H, d, 3.5 Hz), 7.25 (1H, d, 3.5
160 68 Hz), 8.34 (1 H, s), 8.39 (1 H, br s), and 9.08 (1 H, s); M/Z 312 (M+H)+; LC 2.13 min. (Method AM). NMR δH (400 MHz, CDCI3) 2.38 (3H, s), 4.79 (2H, d, J 6.4 Hz), 6.16 (1H, d, 3.3 Hz), 7.20 (1H, d, J 3.3 Hz), 7.32 (1H, t, J 7.6 Hz), 7.47
161 63 (1H, t, 7.6 Hz), 7.56 (1H, d, J 7.7 Hz), 7.62 (1H, d, J 7.8 Hz), 8.26 (1 H, s), 8.31 (1 H, br s) and 9.00 (1 H, s); M/Z 362 (M+H)+; LC 2.72 min. (Method AM). NMR δH (400 MHz, CDCI3) 2.38 (3H, s), 4.62 (2H, d, J 6.1 Hz), 6.16 (1H, d, 3.3 Hz), 7.20 (1H, d, J3.4 Hz), 7.31 - 7.23 (5H, m), 8.25 (1H,
162 68 br s), 8.27 (1H, s) and 8.99 (1H, s); M/Z 294 (M+H)+; LC 2.55 min. (Method AM). IR vmax (DR)/cnrϊ13322, 3199, 1678, 1627, 1462, 1379, 1217, 1127 and 1022; NMR δH (400 MHz, DMSO) 1.17 (6H, d, J6.4 Hz), 2.39 (3H, s), 3.71 (1H, pent, 6.0 Hz), 4.55 (2H, s), 4.58 (2H, d, 6.0 Hz), 6.34 (1H,
163 12 dd, J3.6, 0.8 Hz), 6.87 (2H, brs), 7.21 (1H, d, J3.2 Hz), 7.23 (1H, s), 7.32 (1H, d, 7.6 Hz), 7.36 (1H, s), 7.77 (1H, t, 7.8 Hz) and 8.95 (1H, t, J6.0Hz);M/Z382(M+H)+ NMR δH (400 MHz, CDCI3) 2.38 (3H, s), 4.75 (2H, d, J 5.5 Hz), 6.16 (1 H, d, J 3.4 Hz), 7.20 - 7.16 (2H, m), 7.28 (1 H, d, J 7.8 Hz), 7.64 (1 H,
164 65 td, J 7.7, 1.8 Hz), 8.26 (1 H, s), 8.57 - 8.55 (1 H, m), 8.95 (1 H, br s) and 9.07 (1H, s); M/Z 295 (M+H)+; LC 2.04 min. (Method AM). NMR δH (400 MHz, CDCI3) 2.25 (3H, s), 2.39 (3H, s), 2.54 (3H, s), 4.64 (2H, d, J6Λ Hz), 6.17 (1H, s), 6.98 - 6.94 (1H, m), 7.32 - 7.30 (1H, m),
165 8.24 (1H, s), 9.13 (1H, s) and 9.55 (1H, s); M/Z 323 (M+H)+; LC 2.05 min. (Method AM). IR vmax (DR)/cm-13319, 3196, 2925, 1679, 1632, 1526, 1470, 1359, 1216, 1133, 1022 and 776; NMR δH (400 MHz, DMSO) 2.08 (3H, s),
166 30 2.39 (3H, s), 3.72 (3H, s), 4.47 (2H, d, J 6.0 Hz), 5.94 (1H, s), 6.33 - 6.34 (1H, m), 6.82 (2H, s), 7.20 (1H, d, J3.5 Hz), 7.34 (1H, s) and 8.66 (1H, d, 6.0 Hz); M/Z 327 (M+H)+ IR vmax (DR)/crn13553, 3413, 3316, 3206, 2923, 1631, 1555, 1462,
167 1359, 1227, 1021, 976, 867 and 704; NMR δH (400 MHz, DMSO) 2.08 (3H, s), 2.47 (3H, d, J 1.0 Hz), 3.72 (3H, s), 4.49 (2H, d, J6.0 Hz), 5.95 (1H, s), 7.07 (2H, s), 7.55 (1H, d, J1.0 Hz), 7.70 (1H, s) and 8.72 (1H, t, J6.0Hz);M/Z344(M+H)+
IR vmax (DR)/cn(V13533, 3193, 2173, 1731, 1469, 1217, 1133, 1023, 860 and 774; NMR δH (400 MHz, DMSO) 2.39 (3H, s), 2.48 (3H, s),
168 44 4.55 (2H, d, J6.0 Hz), 6.34-6.35 (1H, m), 6.88 (2H, s), 7.14 (2H, t, J 8.0 Hz), 7.21 (1H, d, J3.0 Hz), 7.37 (1H, s), 7.65 (1H, t, J, 7.5 Hz) and 8.92 (1H, t, 6.0 Hz); M/Z 324 (M+H)+ IR vmax (DR)/cπV1 3516, 3392, 3176, 2921 , 2234, 1519, 1470, 1404, 1243, 1216, 1135, 1025 and 768; NMR δH (400 MHz, DMSO) 2.39 (3H,
169 10 s), 3.79 (3H, s), 4.30 (2H, d, J 6.0 Hz), 6.33 - 6.34 (1H, m), 6.82 (2H, s), 7.19 (1 H, d, J 3.0 Hz), 7.34 (1 H, s), 7.37 (1 H, s), 7.62 (1 H, s) and 8.47 (1 H, t, J6.0 Hz); M/Z 313 (M+H)+ IR vmax (DR)/cπV13321, 3184, 2921, 1733, 1690, 1644, 1589, 1550, 1456, 1355, 1261, 995 and 748; NMR δH (400 MHz, DMSO) 2.47 (3H,
170 d, J 1.0 Hz), 4.62 (2H, d, J6.0 Hz), 7.17 (2H, s), 7.45 - 7.46 (1H, m), 7.58 (1H, d, 1.0 Hz), 7.72 (1H, s), 8.74 (1H, d, 5.0 Hz) and 9.11 - 9.14 (2H,m); M/Z 328 (M+H)+ IR vmax (DR)/cm-13569, 3470, 3348, 2924, 1671, 1622, 1451, 1346, 1226, 1138, 854 and 737; NMR δH (400 MHz, DMSO) 2.34 (3H, d, J 1.0
171 14 Hz), 2.47 (3H, d, J1.0 Hz), 4.73 (2H, d, J6.0 Hz), 7.16-7.17 (3H, m), 7.58 (1 H, s), 7.71 (1 H, s) and 9.22 (1 H, t, J6.0 Hz); M/Z 347 (M+H)+ IR vmax (DR)/cm"13527, 3327, 3219, 2922, 1685, 1633, 1561, 1490, 1469, 1355, 1223 and 737; NMR δH (400 MHz, DMSO) 2.24 (3H, s),
172 2.47 (3H, d, J1.0 Hz), 3.69 (3H, s), 4.28 (2H, d, J5.5 Hz), 7.08 (2H, s), 7.31 (1H, s), 7.55 (1H, d, 1.0 Hz), 7.70 (1H, s) and 8.40 (1H, t, 6.0 Hz); M/Z 344 (M+H)+ IR vmax (DR)/cm-13568, 3495, 3414, 3318, 3210, 3073, 2921, 1733, 1631, 1519, 1356, 1226, 1177, 977 and 703; NMR δH (400 MHz,
173 29 DMSO) 2.12 (3H, s), 2.47 (3H, d, J 1.0 Hz), 3.71 (3H, s), 4.28 (2H, d, J 5.5 Hz), 7.09 (2H, s), 7.53 (1H, s), 7.55 (1H, d, J 1.0 Hz), 7.71 (1H, s) and 8.38 (1H, t, J6.0 Hz); M/Z 344 (M+H)+ IR vmax (DR)/cnT13557, 3462, 3347, 2932, 2161, 1623, 1557, 1454,
174 12 1358, 1271, 1238, 1137, 1034, 868 and 705; NMR δH (400 MHz, DMSO) 2.47 (3H, s), 4.52 (2H, d, 6.0 Hz), 7.06 (2H, s), 7.36 (1H, dd,
Figure imgf000087_0001
Figure imgf000088_0001
NMR δH (400 MHz, CDCI3) 2.33 (3H, s), 2.40 (3H, s), 4.64 (2H, d, J 5.9 Hz), 7.05 (2H, br s), 7.27 (2H, dd, J 4.7, 7.6 Hz), 7.36 (2H, m), 7.64
189 42 (1H, s), 7.91 (1 H, d, J 7.6 Hz), 7.96 (1H, br s), 8.42 (1H, dd, J 0.9, 4.7 Hz) and 9.11 (1 H, t, 5.9 Hz); M/Z 334 (M+H)+; LC 2.26 min. (Method AM). NMR δH (400 MHz, CDCI3) 2.33 (3H, s), 2.38 (3H, s), 4.62 (2H, d, J 6.0 Hz), 7.02 (2H, br s), 7.27 (1 H, dd, 4.8, 7.4 Hz), 7.32 (2H, d, 8.2 Hz),
190 18 7.62 (1 H, s), 7.64 (1 H br s), 8.04 (2H, d, 8.2 Hz), 8.41 (1 H, d, J 3.8 Hz) and 9.11 (1H, t, J 6.0 Hz); M/Z 334 (M+H)+; LC 2.25 min. (Method AM). NMR δH (400 MHz, CDCI3) 2.33 (3H, s), 4.64 (2H, d, J 5.9 Hz), 7.19 (2H, br s), 7.27 (1 H, dd, J 4.9, 7.5 Hz), 7.64 (1 H, d, J 7.5 Hz), 7.74 (1 H,
191 24 t, 7.8 Hz), 7.76 (1 H, s), 8.01 (1 H, d, J 7.8 Hz), 8.41 (1 H, d, J 3.9 Hz), 8.47 (1H, d, J 8.1 Hz), 8.59 (1H, br s) and 9.13 (1H, t, 5.9 Hz); M/Z 345 (M+H)+; LC 2.07 min. (Method AM). NMR δH (400 MHz, CDCI3); 2.39 (3H, s), 4.63 (2H, d, J 5.9 Hz), 6.96 (2H, br s), 7.35 (4H, m), 7.61 (1 H, s), 7.77 (1 H, dt, J 1.8, 7.7 Hz), 7.91
192 11 (1 H, d, J 7.7 Hz), 7.96 (1 H, br s), 8.54 (1 H, d, J 4.3 Hz) and 9.02 (1 H, t, 5.9 Hz); M/Z 320 (M+H)+; LC 2.18 min. (Method AM). NMR δH (400 MHz, CDCI3) 3.84 (3H, s), 4.62 (2H, d, J 5.9 Hz), 7.00 (2H, br s), 7.12 (1 H, dd, J 1.7, 7.6 Hz), 7.29 (1H, dd, J 0.6, 4.8 Hz),
193 7.36 (1 H, d, J 7.9 Hz), 7.44 (1 H, t, J 7.9 Hz), 7.61 (1 H, s), 7.66 (2H, m), 7.77 (1 H, dt, J 17, 7.6 Hz), 8.53 (1 H, dd, J 0.6, 4.8 Hz) and 9.03 (1 H, t, 5.9 Hz); M/Z 336 (M+H)+; LC 2.07 min. (Method AM). NMR δH (400 MHz, CDCI3) 2.33 (3H, s), 3.84 (3H, s), 4.62 (2H, d, J 5.9 Hz), 7.07 (2H, br s), 7.11 (1 H, dd, J 1.5, 8.1 Hz), 7.27 (1H, dd, J 4.6,
194 7.5 Hz), 7.44 (1H, t, 8.0 Hz), 7.63 (1 H, s), 7.66 (2H, m), 7.68 (1 H, dt, J 1.3, 7.5 Hz), 8.41 (1 H, dd, J 1.0, 4.6 Hz) and 9.11 (1 H, t, J 5.9 Hz); M/Z 350 (M+H)+; LC 2.03 min. (Method AM). NMR δH (400 MHz, CDCI3) 2.33 (3H, s), 4.63 (2H, d, J 5.9 Hz), 7.07 (2H, br s), 7.27 (2H, dd, 4.8, 7.5 Hz), 7.52 (1H, d, J 1.8 Hz), 7.54 (2H,
195 16 d, J 1.8 Hz), 7.65 (1 H, s), 8.13 (2H, m), 8.42 (1 H, d, J3.9 Hz) and 9.12 (1 H, t, J5.9 Hz); M/Z 320 (M+H)+; LC 1.98 min. (Method AM). Adenosine Receptor Binding
Binding Affinities at hA2A Receptors The compounds were examined in an assay measuring in vitro binding to human adenosine A2A receptors by determining the displacement of the adenosine A2A receptor selective radioligand [3H]-CGS 21680 using standard techniques.
In general, the compounds of the above examples have a Kj of <5 μM in this assay, demonstrating binding affinity for the human adenosine A2A receptor.
By way of illustration only, the compound of Example 1 has a K of <50 nM in this assay, demonstrating potent binding affinity for the human adenosine A2A receptor.
Evaluation of potential anti-Parkinsonian activity in vivo
Haloperidol-induced hypolocomotion model
It has previously been demonstrated that adenosine antagonists, such as theophylline, can reverse the behavioural depressant effects of dopamine antagonists, such as haloperidol, in rodents (Mandhane S.N. et al., Adenosine A2 receptors modulate haloperidol-induced catalepsy in rats. Eur. J. Pharmacol. 1997, 328, 135 - 141). This approach is also considered a valid method for screening drugs with potential antiparkinsonian effects. Thus, the ability of novel adenosine antagonists to block haloperidol-induced deficits in locomotor activity in mice can be used to assess both in vivo and potential antiparkinsonian efficacy.
Method
Female TO mice (25-30g) obtained from Harlan, UK, are used for all experiments. Animals are housed in groups of 8 [cage size - 40 (width) x 40 (length) x 20 ( height)cm] under 12 h light/dark cycle (lights on 08:00hr), in a temperature (20 ± 2°C) and humidity (55 ± 15%) controlled environment. Animals have free access to food and water, and are allowed at least 3 days to acclimatize after delivery before experimental use.
Drugs Liquid injectable haloperidol (1 ml Serenance ampoules from Baker Norton, Harlow, Essex, each containing haloperidol BP 5 mg) are diluted to a final concentration of 0.02 mg/ml using saline. Test compounds are typically prepared as aqueous suspensions in 1 % methyl cellulose. All compounds are administered orally in a volume of 10 ml/kg.
Procedure 1.5 h before testing, mice are administered 0.2 mg/kg haloperidol, a dose that reduces baseline locomotor activity by at least 50 %. Test substances are typically administered 5 - 60 min. prior to testing. The animals are then placed individually into clean, clear polycarbonate cages [20 (width) x 40 (length) x 20 (height) cm, with a flat perforated, Perspex lid]. Horizontal locomotor activity is determined by placing the cages within a frame containing a 4 x 7 array of photocells linked to a computer, which tabulates beam breaks. Mice are left undisturbed to explore for up to 1 h, and the number of beams breaks made during this period serves as a record of locomotor activity which is compared with data for control animals for statistically significant differences.
By way of illustration only, the compound of example 1 above is orally active in this model at a dose of 30 mg/kg:-
6-OHDA Model
An alternative model of Parkinson's Disease for assessment of the compounds of the invention is as follows.
Parkinson's disease is a progressive neurodegenerative disorder characterised by symptoms of muscle rigidity, tremor, paucity of movement (hypokinesia), and postural instability. It has been established for some time that the primary deficit in PD is a loss of dopaminergic neurones in the substantia nigra which project to the striatum, and indeed a substantial proportion of striatal dopamine is lost (ca 80-85%) before symptoms are observed. The loss of striatal dopamine results in abnormal activity of the basal ganglia, a series of nuclei which regulate smooth and well co-ordinated movement (Blandini F. etal., Glutamate and Parkinson's Disease. Mol. Neurobiol. 1996, 12, 73 - 94). The neurochemical deficits seen in Parkinson's disease can be reproduced by local injection of the dopaminergic neurotoxin 6-hydroxydopamine into brain regions containing either the cell bodies or axonal fibres of the nigrostriatal neurones.
By unilaterally lesioning the nigrostriatal pathway on only one-side of the brain, a behavioural asymmetry in movement inhibition is observed. Although unilaterally-lesioned animals are still mobile and capable of self maintenance, the remaining dopamine- sensitive neurones on the lesioned side become supersensitive to stimulation. This is demonstrated by the observation that following systemic administration of dopamine agonists, such as apomorphine, animals show a pronounced rotation in a direction contralateral to the side of lesioning. The ability of compounds to induce contralateral rotations in 6-OHDA lesioned rats has proven to be a sensitive model to predict drug efficacy in the treatment of Parkinson's Disease.
Animals
Male Sprague-Dawley rats, obtained from Charles River, are used for all experiments. Animals are housed in groups of 5 under 12hr light/dark cycle (lights on 08:00hr), in a temperature (20 ± 2°C) and humidity (55 ± 15%) controlled environment. Animals have free access to food and water, and are allowed at least 7 days to acclimatize after delivery before experimental use.
Drugs
Ascorbic acid, desipramine, 6-OHDA and apomorphine (Sigma-Aldrich, Poole, UK). 6- OHDA is freshly prepared as a solution in 0.2% ascorbate at a concentration of 4 mg/mL prior to surgery. Desipramine is dissolved in warm saline, and administered in a volume of 1 ml/kg. Apomorphine is dissolved in 0.02% ascorbate and administered in a volume of 2 ml_/kg. Test compounds are suspended in 1 % methyl cellulose and injected in a volume of 2 mL kg.
Surgery
15 minutes prior to surgery, animals are given an intraperitoneal injection of the noradrenergic uptake inhibitor desipramine (25 mg/kg) to prevent damage to non- dopamine neurones. Animals are then placed in an anaesthetic chamber and anaesthetised using a mixture of oxygen and isoflurane. Once unconscious, the animals are transferred to a stereotaxic frame, where anaesthesia is maintained through a mask. The top of the animal's head is shaved and sterilised using an iodine solution. Once dry, a 2 cm long incision is made along the midline of the scalp and the skin retracted and clipped back to expose the skull. A small hole is then drilled through the skill above the injection site. In order to lesion the nigrostriatal pathway, the injection cannula is slowly lowered to position above the right medial forebrain bundle at -3.2 mm anterior posterior, -1.5 mm medial lateral from bregma, and to a depth of 7.2 mm below the duramater. 2 minutes after lowing the cannula, 2 μL of 6-OHDA solution is infused at a rate of 0.5 μL/min over 4 minutes, yielding a final dose of 8 μg. The cannula is then left in place for a further 5 minutes to facilitate diffusion before being slowly withdrawn. The skin is then sutured shut using Ethicon W501 Mersilk, and the animal removed from the strereotaxic frame and returned to its homecage. The rats are allowed 2 weeks to recover from surgery before behavioural testing.
Apparatus
Rotational behaviour is measured using an eight station rotameter system provided by Med Associates, San Diego, USA. Each station is comprised of a stainless steel bowl (45 cm diameter x 15 cm high) enclosed in a transparent Plexiglas cover running around the edge of the bowl, and extending to a height of 29 cm. To assess rotation, rats are placed in cloth jacket attached to a spring tether connected to optical rotameter positioned above the bowl, which assesses movement to the left or right either as partial (45s) or full (360Q) rotations. All eight stations are interfaced to a computer that tabulated data.
Procedure
To reduce stress during drug testing, rats are initially habituated to the apparatus for 15 minutes on four consecutive days. On the test day, rats are given an intraperitoneal injection of test compound 30 minutes prior to testing. Immediately prior to testing, animals are given a subcutaneous injection of a subthreshold dose of apomorphine, then placed in the harness and the number of rotations recorded for one hour. The total number of full contralateral rotations during the hour test period serves as an index of antiparkinsonian drug efficacy.

Claims

1. The use of a compound of formula (1):
Figure imgf000094_0001
(I) wherein
Figure imgf000094_0002
R2 is optionally substituted aryl or heteroaryl attached via a carbon atom;
R3 is H; optionally substituted CrC6alkyl, C2-C6alkenyl, C2-C6alkynyl, or C3-C7 cycloalkyl, halogen; OH or OR10;
R4 is H, optionally substituted Cι-C6alkyl, C3-C6alkenyl, C3-C6alkynyl, C3-C7 cycloalkyl, aryl or heteroaryl,
R5 is H or optionally substituted Cι-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, or C3-C7 cycloalkyl; or R4 and R5 together form a 5 or 6-membered heterocyclic ring; R10 is optionally substituted CrC6alkyl;
and pharmaceutically acceptable salts and prodrugs thereof, in the manufacture of a medicament for the treatment or prevention of a disorder in which the blocking of purine receptors is beneficial, PROVIDED THAT when R2 is optionally substituted aryl the said use is not the manufacture of a medicament for the treatment or prevention of inflammatory pain.
2. The use as claimed in claim 1 wherein R2 is optionally substituted phenyl.
3. The use as claimed in claim 1 wherein R2 is optionally substituted monocyclic or bicyclic heteroaryl.
4. The use as claimed in claim 1 wherein R2 is optionally substituted furyl, thienyl, thiazolyl, oxazolyl, imidazolyl, pyridyl, indolyl or benzofuranyl.
5. The use as claimed in any of the preceding claims wherein optional substituents present in R2 are selected from CrC3 alkyl, C1-C3 alkoxy and carboxamide groups.
6. The use as claimed in any of claims 1 to 4 wherein optional substituents present in R2 are selected from methyl, ethyl, methoxy, ethoxy, cyano, chloro, bromo, fluoro, trifluoromethyl, and carboxamide groups -CONRARB where RA and RB are independently hydrogen, methyl or ethyl. 5
7. The use as claimed in claim 1 wherein R2 is 2-furyl, 5-methyl-2-furyl, 2-thiazolyl, 4- methyl-2-thiazolyl, phenyl, 3-cyano-phenyl, or o-methyl-phenyl.
8. The use as claimed in any of the preceding claims wherein R3 is H, CrC6alkyl, C3-C6 10 cycloalkyl, halo substituted G|-C6alkyl, or halogen.
9. The use as claimed in any of claims 1 to 7 wherein R3 is H, methyl, ethyl, n- or isopropyl, cyclopropyl, n-, sec- or tert-butyl, trifloromethyl, chloro, bromo or fluoro.
15 10. The use as claimed in any of the preceding claims wherein R4 is CrC6alkyl, substituted by aryl or heteroaryl, the said aryl or heteroaryl ring being optionally substituted.
11. The use as claimed in any of claims 1 to 9 wherein R4 is arylmethyl or 20 heteroarylmethyl, the said aryl or heteroaryl ring being optionally substituted.
12. The use as claimed in any of the preceding claims wherein R4 is aryl or heteroaryl or includes an aryl or heteroaryl ring, said ring being selected from optionally substituted phenyl, pyridyl, furanyl, thienyl, isoxazolyl, thiazolyl, pyrrolyl, imidazolyl, pyrazolyl,
25 pyrazinyl, pyrimidinyl, benzimidazolyl, indolyl, benzthiazolyl, benzthiadiazolyl, quinolyl, and isoquinolyl.
13. The use as claimed in any of claims 1 to 9 wherein R4 is aryl or heteroaryl or includes an aryl or heteroaryl ring, said ring being selected from optionally substituted
30 phenyl, pyridyl, imidazolyl, pyrazolyl, and isoxazolyl.
14. The use as claimed in any of claims 10 to 13 wherein optional substituents of R4 are selected from d-C6 alkyl, C C3 alkoxy, Cι-C3 alkoxy-(CrC3 alkyl)-, chloro, bromo, fluoro, trifluoromethyl, -NRARB, -CONRARB, -NRACORB where RA and RB are
35 independently hydrogen or d-C3 alkyl or together form an optionally substituted 5 or 6- membered heterocyclic ring.
15. The use as claimed in any of the preceding claims wherein R5 is hydrogen.
16. The use as claimed in any of claims 1 to 9 wherein R and Rs taken together with the 5 nitrogen to which they are attached form a saturated 5 or 6-membered heterocyclic ring, optionally benzo-fused.
17. The use as claimed in any of claims 1 to 9 wherein R4 and R5 taken together with the nitrogen to which they are attached form a dihydroindolyl, dihydroisoindolyl,
10 tetrahydroquinolinyl or tetrahydroisoquinolinyl ring system.
18. A method of treating or preventing a disorder in which the blocking of purine receptors is beneficial, the method comprising administration to a subject in need of such treatment an effective dose of a compound of formula (I) as set out in any of claims 1 to
15 17 or a pharmaceutically acceptable salt or prodrug thereof.
19. A compound of formula (I) as defined in any of claims 1 to 17, PROVIDED THAT: (a) R2 is not an optionally substituted pyrazolopyridine ring system; and (b) when Ri and R3 are hydrogen and R2 is unsubstituted phenyl then -NR4R5 is not -NH2, NHCH3 or -
20 N(CH3)2; and (c) when Ri is -NH2 and R3 is hydrogen, then R2 is not phenyl or phenyl substituted by one or more substituents selected from halogen, hydroxy, C C6 alkyl, C C6 alkoxy, nitro, -NH2, or-NHCOCH3.
20. A compound as claimed in claim 19 wherein Ri is -NH2 and R3 is hydrogen, and 25 R2 is substituted phenyl, the substituent(s) in the phenyl being selected from, methylenedioxy, C C6 alkylthio, trifluromethyl, trifluoromethoxy, nitrile (-CN), oxo, CORA, - CONHRA, -CONRARB, -NHRA, NRARB, -NHCOR0, -NHCOORA, -NRBCOORA wherein RA and RB are independently a C C6 alkyl group and wherein Rc is a C2-C6 alkyl group.
30 21. A compound as claimed in claim 19 wherein the compound is selected from any of the compounds as shown in Table 1.
22. For use in therapy a compound as claimed in any of claims 19 to 21.
35 23. A pharmaceutical composition comprising a compound as claimed in any of claims 19 to 21 in combination with a pharmaceutically acceptable carrier or excipients.
24. A use as claimed in any of claims 1 to 17 or a method as claimed in claim 18 wherein said receptors are adenosine receptors.
25. A use as claimed in any of claims 1 to 17 or a method as claimed in claim 18 wherein said receptors are adenosine A2A receptors.
26. A use as claimed in any of claims 1 to 17 or a method as claimed in claim 18 wherein the disorders are selected from movement disorders; acute and chronic pain other than inflammatory pain; anxiety disorders, affective disorders; central and peripheral nervous system degenerative disorders; schizophrenia; cognitive and memory impairment disorders; attention disorders; central nervous system injury; cerebral ischaemia; myocardial ischaemia; muscle ischaemia; sleep disorders; eye disorders; cardiovascular disorders; and diabetes.
27. A use or method as claimed in claim 26 wherein the movement disorder is selected from Parkinson's disease, progressive supernuclear palsy, Huntingtons disease, multiple system atrophy, corticobasal degeneration, Wilsons disease, Hallerrorden-Spatz disease, progressive pallidal atrophy, Dopa-responsive dystonia-Parkinsonism and spasticity.
28. A use or method as claimed in claim 26 or claim 27, wherein the disorder is a movement disorder and the compound of formula (I) is used or administered together with L-DOPA or a dopamine agonist.
29. A use or method as claimed in claim 26 wherein the anxiety disorder is selected from panic disorder, agorophobia, obsessive compulsive disorder, social phobia, post traumatic stress disorder, generalised anxiety disorder and specific phobia.
30. A use or method as claimed in claim 26 or claim 27 wherein the disorder is pain.
31. A use or method as claimed in claim 26 or claim 27 wherein the disorder is neuropathic pain.
32. A use or method as claimed in claim 26 wherein said affective disorder is selected from bipolar disorder, seasonal affective disorder, depression, manic depression, atypical depression and monodepressive disease.
33. A use or method as claimed in claim 26 wherein said central and peripheral nervous system degenerative disorder is selected from corticobasal degeneration, demyelinating disease, Freidrich's ataxia, motoneurone disease, multiple system atrophy, myelopathy, radiculopathy, peripheral neuropathy, systemic lupus erythamatosis, granulomatous disease, olivo-ponto-cerebellar atrophy, progressive pallidal atrophy, progressive supranuclear palsy and spasticity.
34. A use or method as claimed in claim 26 wherein said cognitive and/or memory impairment disorder is selected from dementia, Alzheimers Disease, Frontotemporal dementia, multi-infarct dementia, AIDS dementia, dementia associated with Huntingtons Disease, Lewy body dementia, senile dementia, age-related memory impairment, cognitive impairment associated with dementia, Korsakoff syndrome and dementia pugilans.
35. A use or method as claimed in claim 26 wherein attention disorder is selected from attention-deficit hyperactivity disorder (ADHD), attention deficit disorder, minimal brain dysfunction, brain-injured child syndrome, hyperkinetic reaction childhood and hyperactive child syndrome.
36. A use or method as claimed in claim 26 wherein said central nervous system injury is selected from traumatic brain injury, surgical trauma, raised intracranial pressure, cerebral oedema, hydrocephalus and spinal cord injury.
37. A use or method as claimed in claim 26 wherein said cerebral ischaemia is transient ischaemic attack, stroke, subarachnoid haemorrhage, cerebral vasospasm, perinatal asphyxia, drowning, cardiac arrest or subdural haematoma.
38. A use or method as claimed in claim 26 wherein the sleep disorder is selected from hypersomnia, narcolepsy and restless legs syndrome.
39. A use or method as claimed in claim 26 wherein the eye disorder is selected from retinal ischaemia-reperfusion injury and diabetic neuropathy.
40. Use of a compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof as set forth in any of claims 1 to 17 in the manufacture of a medicament for neuroprotection in a subject.
41. A method of neuroprotection comprising administration to a subject in need of such treatment an effective dose of a compound of formula (I) as set out in any of claims 1 to 17 or a pharmaceutically acceptable salt or prodrug thereof.
PCT/GB2005/000498 2004-02-12 2005-02-11 Pyrimidine compounds as purine receptor antagonist WO2005079801A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/588,757 US7875600B2 (en) 2004-02-12 2005-02-11 Pyrimidine compounds as purine receptor antagonist
EP05708321A EP1720553A1 (en) 2004-02-12 2005-02-11 Pyrimidine compounds as purine receptor antagonist

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0403155.5 2004-02-12
GBGB0403155.5A GB0403155D0 (en) 2004-02-12 2004-02-12 Chemical compounds

Publications (1)

Publication Number Publication Date
WO2005079801A1 true WO2005079801A1 (en) 2005-09-01

Family

ID=32011815

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/GB2005/000497 WO2005079800A1 (en) 2004-02-12 2005-02-11 Pyrimidine compounds as purine receptor antagonist
PCT/GB2005/000498 WO2005079801A1 (en) 2004-02-12 2005-02-11 Pyrimidine compounds as purine receptor antagonist

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/GB2005/000497 WO2005079800A1 (en) 2004-02-12 2005-02-11 Pyrimidine compounds as purine receptor antagonist

Country Status (6)

Country Link
US (2) US20080182860A1 (en)
EP (2) EP1722798B1 (en)
AT (1) ATE485044T1 (en)
DE (1) DE602005024239D1 (en)
GB (1) GB0403155D0 (en)
WO (2) WO2005079800A1 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006084017A2 (en) * 2005-02-04 2006-08-10 Bristol-Myers Squibb Company Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
EP2184273A1 (en) 2008-11-05 2010-05-12 Bayer CropScience AG Halogen substituted compounds as pesticides
EP2253617A1 (en) 2009-05-20 2010-11-24 Bayer CropScience AG Halogenated compounds as pesticides
JP2011529969A (en) * 2008-08-04 2011-12-15 シーエイチディーアイ ファウンデーション，インコーポレーテッド Specific kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions and methods of their use
JP2012507533A (en) * 2008-10-31 2012-03-29 メルク・シャープ・エンド・ドーム・コーポレイション Technical field of P2X3 receptor antagonist for the treatment of pain
WO2012126766A1 (en) 2011-03-18 2012-09-27 Bayer Cropscience Ag N-(3-carbamoylphenyl)-1h-pyrazole-5-carboxamide derivatives and the use thereof for controlling animal pests
US9428464B2 (en) 2011-08-30 2016-08-30 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
CN105934428A (en) * 2013-11-27 2016-09-07 拜耳作物科学股份公司 Process for the preparation of 5-fluoro-1h-pyrazoles
US9981918B2 (en) 2011-08-30 2018-05-29 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
US10258621B2 (en) 2014-07-17 2019-04-16 Chdi Foundation, Inc. Methods and compositions for treating HIV-related disorders

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006251624A1 (en) * 2005-05-24 2006-11-30 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding cassette transporters
EP1829867A1 (en) * 2006-03-03 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Imidazole compounds having pharmaceutical activity towards the sigma receptor
BRPI0814672A2 (en) * 2007-07-23 2014-09-30 Synosia Therapeutics METHOD OF TREATING A PATIENT, AND POST-TRAUMATIC STRESS DISTURBANCE, AND METHODS FOR IMPROVING RESILIENCE IN A PATIENT AND DIAGNOSING DIAGNOSIS IN A PATIENT.
EP2185537A1 (en) * 2007-08-02 2010-05-19 Pfizer Inc. Pyrimidine and pyridine derivatives and their pharmaceutical use and compositions
WO2009106209A1 (en) * 2008-02-27 2009-09-03 Merck Patent Gmbh Carboxamide-heteroaryl derivatives for the treatment of diabetes
WO2009127678A1 (en) * 2008-04-17 2009-10-22 Glaxo Group Limited Indoles as modulators of nicotinic acetylcholin receptor subtype alpha-71
AU2009327127C1 (en) 2008-12-19 2017-03-09 Centrexion Therapeutics Corporation Cyclic pyrimidin-4-carboxamides as CCR2 receptor antagonists for treatment of inflammation, asthma and COPD
AU2010238518A1 (en) * 2009-04-16 2011-12-01 Proximagen Limited Indole derivative modulators of the alpha 7 nAChR
CN102933579B (en) 2009-12-17 2015-07-15 贝林格尔.英格海姆国际有限公司 New ccr2 receptor antagonists and uses thereof
JP5721242B2 (en) 2010-06-01 2015-05-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Novel CCR2 antagonist
WO2012031383A1 (en) * 2010-09-06 2012-03-15 中国科学院广州生物医药与健康研究院 Amide compounds
AU2013216935C1 (en) * 2012-02-08 2017-12-14 John Emmerson Campbell Heteroaryl compounds and methods of use thereof
TWI636047B (en) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 Heterocyclic derivatives
CN105683179B (en) * 2013-08-14 2018-10-26 卡尔维斯塔制药有限公司 The inhibitor of plasma kallikrein
US9611252B2 (en) 2013-12-30 2017-04-04 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
WO2015103317A1 (en) * 2013-12-30 2015-07-09 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
AU2015289643B2 (en) * 2014-07-16 2020-10-22 Attune Pharmaceuticals, Inc. Therapeutic inhibitory compounds
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
CA2990460C (en) 2015-07-02 2023-10-17 Centrexion Therapeutics Corporation (4-((3r,4r)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2r,6s)-6-(p-tolyl)tetrahydro-2h-pyran-2-yl)methylamino)pyrimidin-4-yl)methanone citrate
KR20220107319A (en) 2016-05-31 2022-08-02 칼비스타 파마슈티컬즈 리미티드 Pyrazole derivatives as plasma kallikrein inhibitors
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
EP3481391A4 (en) 2016-07-11 2020-03-11 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
WO2018023072A2 (en) 2016-07-29 2018-02-01 Sunovion Pharmaceuticals, Inc. Compounds and compositions and uses thereof
EP3490607A4 (en) 2016-07-29 2020-04-08 Sunovion Pharmaceuticals Inc. Compounds and compositions and uses thereof
US10738007B2 (en) * 2016-10-24 2020-08-11 Translation Drug Development, LLC Amide compounds as kinase inhibitors, compositions and methods of treatment
JP7191085B2 (en) 2017-08-02 2022-12-16 サノビオン ファーマシューティカルズ インク Isochroman compounds and uses thereof
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
HRP20220367T1 (en) 2017-11-29 2022-05-27 Kalvista Pharmaceuticals Limited Dosage forms comprising a plasma kallikrein inhibitor
EP3575287A1 (en) * 2018-05-31 2019-12-04 Universiteit Leiden Inhibitors of n-acylphosphatidylethanolamine phospholipase d (nape-pld)
US20220017483A1 (en) 2018-12-28 2022-01-20 Sichuan-Kelun-Biotech Biopharmaceutical Co., Ltd Aminopyridine compound, preparation method therefor and use thereof
MX2021010880A (en) 2019-03-14 2022-01-18 Sunovion Pharmaceuticals Inc Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof.
EP4010333A1 (en) 2019-08-09 2022-06-15 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002055084A1 (en) * 2001-01-10 2002-07-18 Vernalis Research Limited PYRROLO[2,3-d]PYRIMIDINE AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS
WO2004029204A2 (en) * 2002-09-27 2004-04-08 Merck & Co., Inc. Substituted pyrimidines
WO2004080979A1 (en) * 2003-03-14 2004-09-23 Lg Life Sciences Ltd. Novel 3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl ketone derivatives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002055084A1 (en) * 2001-01-10 2002-07-18 Vernalis Research Limited PYRROLO[2,3-d]PYRIMIDINE AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS
WO2004029204A2 (en) * 2002-09-27 2004-04-08 Merck & Co., Inc. Substituted pyrimidines
WO2004080979A1 (en) * 2003-03-14 2004-09-23 Lg Life Sciences Ltd. Novel 3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl ketone derivatives

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
OBRECHT D ET AL: "5. A NOVEL AND EFFICIENT APPROACH FOR THE COMBINATORIAL SYNTHESIS OF STRUCTURALLY DIVERSE PYRIMIDINES ON SOLID SUPPORT", HELVETICA CHIMICA ACTA, VERLAG HELVETICA CHIMICA ACTA. BASEL, CH, vol. 80, 1997, pages 65 - 72, XP002915327, ISSN: 0018-019X *
SAKAMOTO, T.; ET AL., CHEM. PHARM. BULL., vol. 28, no. 1, 1980, pages 202 - 207, XP001206935 *
TAKAO, S.; ET AL., CHEM. PHARM. BULL., vol. 28, no. 2, 1980, pages 571 - 577, XP001206934 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006084017A3 (en) * 2005-02-04 2006-12-14 Bristol Myers Squibb Co Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
WO2006084017A2 (en) * 2005-02-04 2006-08-10 Bristol-Myers Squibb Company Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
US7923556B2 (en) 2005-02-04 2011-04-12 Bristol-Myers Squibb Company Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
JP2011529969A (en) * 2008-08-04 2011-12-15 シーエイチディーアイ ファウンデーション，インコーポレーテッド Specific kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions and methods of their use
US9145373B2 (en) 2008-08-04 2015-09-29 Chdi Foundation, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
JP2012507533A (en) * 2008-10-31 2012-03-29 メルク・シャープ・エンド・ドーム・コーポレイション Technical field of P2X3 receptor antagonist for the treatment of pain
US8946234B2 (en) 2008-11-05 2015-02-03 Bayer Cropscience Ag Halogen-substituted compounds
EP2184273A1 (en) 2008-11-05 2010-05-12 Bayer CropScience AG Halogen substituted compounds as pesticides
EP2253617A1 (en) 2009-05-20 2010-11-24 Bayer CropScience AG Halogenated compounds as pesticides
WO2012126766A1 (en) 2011-03-18 2012-09-27 Bayer Cropscience Ag N-(3-carbamoylphenyl)-1h-pyrazole-5-carboxamide derivatives and the use thereof for controlling animal pests
US9428464B2 (en) 2011-08-30 2016-08-30 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
US9981918B2 (en) 2011-08-30 2018-05-29 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
CN105934428A (en) * 2013-11-27 2016-09-07 拜耳作物科学股份公司 Process for the preparation of 5-fluoro-1h-pyrazoles
CN105934428B (en) * 2013-11-27 2019-07-19 拜耳动物保健有限责任公司 The method for preparing the fluoro- 1H- pyrazoles of 5-
US10258621B2 (en) 2014-07-17 2019-04-16 Chdi Foundation, Inc. Methods and compositions for treating HIV-related disorders

Also Published As

Publication number Publication date
ATE485044T1 (en) 2010-11-15
US7875600B2 (en) 2011-01-25
DE602005024239D1 (en) 2010-12-02
WO2005079800A1 (en) 2005-09-01
EP1722798B1 (en) 2010-10-20
EP1722798A1 (en) 2006-11-22
US20080182860A1 (en) 2008-07-31
US20070281936A1 (en) 2007-12-06
EP1720553A1 (en) 2006-11-15
GB0403155D0 (en) 2004-03-17

Similar Documents

Publication Publication Date Title
US7875600B2 (en) Pyrimidine compounds as purine receptor antagonist
US7087754B2 (en) Pyrazolo[3,4-d]pyrimidine derivatives and their use as purinergic receptor antagonists
JP5202259B2 (en) Triazolo [4,5-d] pyrimidine derivatives and their use as purinergic receptor antagonists
US6787541B1 (en) Thieno-and furopyrimidine derivatives as A2A-receptor antagonists
EP1349857B1 (en) Purine derivatives as purinergic receptor antagonists
US20060128731A1 (en) Pyrrolo [2,3-d] pyrimidine and their use as purinergic receptor antagonists
JP4390454B2 (en) Thieno (3,2-d) pyrimidine and furano (3,2-d) pyrimidine and their use as purinergic receptor antagonists
AU2009263976A1 (en) Triazolo [4, 5-d] pyramidine derivatives and their use as purine receptor antagonists
AU2002219355A1 (en) Triazolo(4,5-d) pyrimidine derivatives and their use as purinergic receptor antagonists
US20100173914A1 (en) Pharmaceuticals, compositions and methods of making and using the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005708321

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005708321

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10588757

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10588757

Country of ref document: US